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A RANDOMIZED ,OPEN LABELLED , SINGLE CENTERED STUDY 
OF METFORMIN IN PREVENTING METABOLIC  SYNDROME 
ASSOCIATED WITH INITIATION OF ATYPICAL ANTIPSYCHOTIC 
THERAPY IN ADOLESCENTS AND YOUNG  ADULTS 
Background: 
        Schizophrenia is a debilitating brain disorder characterized by a chronic   
remitting and relapsing course of psychosis that is superimposed on persistent  
"deficit" features such as negative symptoms and cognitive dysfunction. 
Metformin  is a  member  of  biguanide  class  of  oral  hypoglycemic  agents. It 
has been tried for the prevention of metabolic syndrome associated with the use 
of atypical antipsychotics.   
Objective: 
     The purpose of the study was to evaluate the effectiveness and safety of  
Metformin along with Risperidone to prevent antipsychotic-induced metabolic  
syndrome in first episode schizophrenia patients. 
Methods: 
      A randomized,open labelled,prospective study was conducted in the 
Department of psychiatry,Tirunelveli medical college from March 2013 to 
February 2014. Around 96 patients with 18 to 40 years of age who have  been 
diagnosed with first episode schizophrenia based on DSM - IV criteria and  on 
treatment with T.Risperidone 2 mg twice a day for ≤ 2 months were enrolled for 
the study.They were randomized into 2 groups. Group1patients were given  T. 
Risperidone (2 mg twice daily,n=48) and group2 Patients were given   
T.Metformin  (500 mg twice  daily,n=48) along  with  T.Risperidone for 6 
months. 
           The primary endpoint assessed was the proportion of patients developing 
metabolic  syndrome at the end of 6 months in both the groups.The secondary 
endpoints were the changes in bodymass index,waist circumference,fasting 
blood sugar and triglycerides from baseline to the end point and the proportion 
of patients  progressing a stage higher from the baseline in terms of BMI at the 
end of 3  months. 
Results: 
         Baseline characteristics were similar in both the  groups ( p>0.05) except  
that the patients in group II had higher BMI levels(p < 0.001) and larger waist  
circumference levels(p = 0.04).Of the 48 patients in group I,10 patients 
developed metabolic syndrome and of the 48 patients in group II,only 1 patient 
developed metabolic syndrome.There was a significant reduction in BMI and 
waist  circumference at the end of 3 months (p < 0.001) and at the end of 6 
months (p < 0.001) when compared to baseline in group II individuals . 
         There is significant reduction in FBS and Triglyceride levels at the end of 
6 months of treatment(p < 0.001) in  group II individuals.When compared to 
group I,significantly lesser  proportion of patients in group II progressed to the 
next stage in terms of  BMI,3 months after treatment.There was significant 
statistical difference between both the groups (p<0.05) in terms of 
BMI,WC,FBS,triglycerides. The treatment emergent adverse effects  with 
Metformin was generally mild and did not lead to any discontinuation. 
Conclusion: 
       The use of Metformin along with Risperidone was safe and effective in  the 
prevention of metabolic syndrome induced by atypical antipsychotics. This may 
have a good impact on the long term cardiovascular morbidity  and mortality of 
the schizophrenia patients .  
 
Keywords:         
       Schizophrenia, Metabolic syndrome, Atypical antipsychotics, Body mass 
index, Waist circumference, Fasting blood sugar, Triglycerides.                  
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Introduction: 
Schizophrenia  is  a  debilitating  brain  disorder  characterized  by  a  
chronic   remitting  and  relapsing  course  of  psychosis  that   is 
superimposed  on  persistent  "deficit"  features  such  as  negative  
symptoms  and  cognitive  dysfunction 
1
.  It  has  a  worldwide  prevalence 
2 
 
of  1 %  and  is  considered  the  prototypic  disorder  for  understanding  the  
phenomenology  of  psychosis 
3
. It  is  associated  with  a  high  morbidity  
and  mortality  resulting  from  strikingly  high  suicide  rate  of  10 % 
4 
. 
The  introduction  of  Chlorpromazine  in  the  late  1950s transformed  
and  formed  a  new  frontier  in  the  clinical  management  of  
Schizophrenia.  Initially, "conventional  neuroleptics" were  developed  
during that  era  and  they  were  found  to  effectively  control  and  improve  
the  disease  symptomatology  but  were  also  associated  with  major  
drawbacks   that  include  parkinsonian  like  movement  disorders.  As  a 
result  of  these  side  effects , newer  neuroleptics (termed  "atypical  
antipsychotics")  were  introduced  into  clinical  use
4
.  Although  the  
concerns  over  extrapyramidal  side  effects  and  tardive  dyskinesia  are  
less  with  these  group  of  drugs , there  has  been  a  co-occurence  of  
atherogenic  dyslipidemia  with  abdominal  adiposity,  impaired  fasting  
glucose,  insulin  resistance  or  overt  Diabetes  Mellitus,  and  Hypertension  
2 
 
that  constitutes  the  cluster  of  clinical  features  known  as  the  Metabolic  
syndrome 
1
.  
Risperidone  which  comes  under  the  group  of  atypical  
antipsychotics  is  a  benzisoxazole  derivative
5
.  According  to  CATIE  
study,  14%  of  patients   receiving  Risperidone  had  been  found  to  have  
more  than  7%  increase  in  weight  from  baseline
1
 . Also  a  meta  analysis  
by  Allison  and  coworkers  has  estimated  that  the  mean  increase  in  
weight  with  Risperidone  to  be  2.1 kg
6
.  It  has  been  assumed  that  
increased  appetite and  central  Histamine  H1  antagonism  along  with  
alteration  of  insulin  sensitivity  and  direct  impairment  of  metabolic  
dysregulation  might  be  the  underlying  cause  for   weight  gain
7
 .These  
metabolic  derangements  not  only  affect  the  compliance  but  inevitably  
also  are  associated  with  substantial  morbidity   (Cardiovasular disease, 
Hypertension and  Diabetes)  and  mortality 
8
.  
Lifestyle  changes  are  found  to  be  the  safe  and  effective  means  
of  controlling  weight  in  patients  taking  these  drugs . However,  these  
sort  of  behaviour  and  dietary  modifications  are  difficult  to  be  instituted  
in  subjects  with   neuropsychiatric  disorders 
9
.   
Metformin,  member  of  Biguanide  class  of  Oral  hypoglycemic  
agents  increases  storage  of  glycogen  in  skeletal  muscles,  lower  rates  of  
production  of  hepatic  glucose,  increases  sensitivity of  insulin  thereby  
3 
 
reducing  blood  glucose  levels
10
.  In  view  of   stemming  down  the  
metabolic  derangements   due  to  atypical  antipsychotics  and  also  due  to  
the  paucity  of  studies  using  Metformin  along  with  Risperidone  in  our  
population,  the  present  study  has  been  designed  to  evaluate  the  
effectiveness  and  safety  of  Metformin  along  with  Risperidone  in  
preventing  antipsychotic - induced  Metabolic  syndrome   in  first  episode  
schizophrenia  patients. 
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REVIEW  OF  LITERATURE: 
Schizophrenia  is  one  of  the  most  debilitating  and  most puzzling  
of  psychiatric  syndromes. It  is  described  as  disordered  cognition,  
including  a  "gain of - function"  in  psychotic  symptoms  and  a  "loss  of  -
function"  in  specific  cognitive  functions , such  as  working  and  
declarative memory but  the  characteristic  finding  of  classical  
neurodegenerative disorders  namely  progressive  dementia  is  absent 
6
. 
HISTORY: 
 Historically,  in  the  most  ancient  document  in  Ayurveda,  
written about  33  centuries  ago,  Charaka  has  described  the  
patient  with schizophrenia  like  illness  as  one  "who  is  
gluttonous,  filthy, walks  naked,  has  lost  his  memory  and  
moves  about  in  an  uneasy manner ".  
 1808 -  Haslam  clearly  described  the  syndrome  clearly.   
 1860 - However  Morel  is  generally  credited  for  his  
description  of  “ Demence  precoce ” 
 1896  -  Emil   kraeplin  formed  the  concept  of  “dementia     
precox”  referring  to  mental  deterioration  starting  early  in  life
6
.  
 1911  -  Eugen  Bleuler  coined  the  term  “  Schizophrenia ”. He  
described  the  four  primary  symptoms  -  Autism, Ambivalence, 
loosening  of  association  and  Affective  flattening . 
5 
 
 Later  half  of  20
th
  century  -  Kurt  Schneider  described  11  
symptoms  whose  presence  in  the  absence  of  coarse  brain  
disease  was  diagnostic  of  Schizophrenia 
11 
. 
MODERN  DIAGNOSTIC  CRITERIA : 
1. First  rank  symptoms  have  stood  the  test  of  time.  These symptoms  
are featured  predominantly  in  the  Diagnostic  and  Statistical  Manual  
of  Mental disorders  (DSM)  as  well  as  International  Classification  of 
Diseases  ( ICD)  of World  Health  Organization. 
2. International  Pilot  Study  of  Schizophrenia   sponsored  by  World  
Health organization  was  the  later  ground  breaking  study  for  the  
adoption  of  explicit ground  breaking  criteria, which  showed  
Schizophrenia   manifested  itself  in  similar  ways  across  very  diverse  
cultures .  
3. The  creation  of  the  Research  Diagnostic  criteria  (RDC)  in 1978  
was  the next  major  step  towards  the  current  diagnostic  criteria  
which  emphasizes  on the  temporal  length  of  observable  
psychopathology  and  differentiation  based on  the  presence  or  
absence  of  mood  symptoms 
6
. 
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CURRENT  DIAGNOSTIC  CRITERIA : 
Diagnostic  and  Stastitical  manual  of  Mental  disorders  (DSM -IV ) 
and International  Classification  of  Diseases  (ICD - 10)  are  the  current  
versions  in  use  now  for  the  diagnosis  of  Schizophrenia 
6
. 
TABLE : 1 
MAJOR  DIAGNOSTIC  CRITERIA 
 
 
 DSM - IV ICD-10 
Characteristic  symptoms 
One  or  more  for  one 
Month 
1. Bizarre  delusions 
2.Commenting  
voices (or) voices  
conversing 
1 . Thought  echo / 
Insertion/ Withdrawal/ 
Broadcasting 
2.Delusions  of  control 
3.Hallucinatory  voices 
4. Persistent  delusions 
Two   (or)  more 
1. Delusions 
2. Hallucinations 
3.Disorganized  
speech 
4.Grossly  
disorganized 
(or) catatonic 
behaviour 
5.Negative 
symptoms 
 
1. Persistent 
Hallucinations 
2.Thought  block / 
Thought  disorder 
3. Catatonia 
4. Negative  symptoms 
5.Significant  personality 
    Change 
7 
 
Time  course 
One month 
(Significant  
proportion) 
For symptoms  listed 
Plus  6 months  
social/ Occupational 
disturbance 
 
One  month 
(Most  of  the  time) 
Exclusions 
Schizoaffective  
disorder (or) brief 
mood  disturbance, 
Direct  effect  Of  
drugs  of  abuse / 
Medication (or)  
general  Medical  
condition 
Extensive  depressive / 
Manic symptoms  (or) 
Diagnosis  of  
schizoaffective  disorder, 
Overt  brain  disease; 
Drug  intoxication / 
Withdrawal 
 
EPIDEMIOLOGY: 
Schizophrenia  constitutes  a  serious  public  health  problem  all  over  
the world . It  is  a  disorder  of  relatively  high  point  prevalence, low  
incidence and  high  disability
11
.  DALY  rate  of  Schizophrenia  in  
Indonesia  is  higher ( 321.870 ) with  India  at  rank  47 ( 268.903 ) and  the  
least  in  Australia  ( 164.255 )
 12
. 
Prevalence: 
Developed  countries  show  point  prevalence  in  the  range  of  2.4  
to  6.7  per  1000  population  at  risk . The  developing  countries  show  
8 
 
prevalence  in  the  range  of  1.4  to  6.8  per  1000  population  at  risk 
6
. 
Estimates  of  China  are  observed  to  be  lower  than  the  other  third  
world  countries .The  point  prevalence  rates  are  uniformly  low  at  
1.8/1000
13
. In  Chennai,  the  prevalence  rate  of  schizophrenia  was  
2.62/1000 
14
. 
Incidence:  
Hafner  et  al 
15
  and  Eaton  et  al 
16 
 have  suggested  that  Ireland , 
Germany  and  United  states  show  higher  incidence  rates (Range  0.5 -
0.7/1000) compared  to  Scandinavia  and England  (Range  0.1 - 0.2 /1000) . 
India  reports  higher  incidence  rates  compared  to  West . West Bengal
17
, 
Chandigarh 
18
 and     Chennai 
19    
report  significant  cases  in  India. 
According  to  a  community  survey , incidence  rates  in  West 
Bengal  were found  to  be 0.93/1000. Chandigarh  reports  an  incidence  
rate  of  0.38/1000  in  urban  areas and  0.44/1000  in  rural  areas  and  the  
rate  in  Chennai  was  found  to  be  0.35/1000. 
Gender: 
Schizophrenia  was  found  equally  prevalent  in  men  and  women . 
The onset  of  schizophrenia  before  10  years  and  60  years  of  age  was  
extremely  rare . For  men,  peak  age  of  onset  was  10  to  25  years  and  
for  women,  it  was  25 - 35 years 
20
. 
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Illness: 
           Several  studies  have  suggested  that  80%  of  patients  with  
schizophrenia   have  significant  concurrent  medical  illnesses.  Around  50  
percent  of  patients  remain  undiagnosed. Risk  of  hospitalization  is  
increased  with  alcohol  abuse 
20
. 
ETIOLOGY
 23
: 
The  exact  etiology  of  Schizophrenia  is  currently  unknown. 
However  several  theories  have  been  proposed; these  include  the  
following. 
I . BIOLOGICAL  THEORIES 
a) Genetic  hypothesis 
b) Biochemical  theories 
c) Neuropathology 
d) Neuroanatomy 
II . PSYCHOLOGICAL  THEORIES 
a) Stress vulnerability  hypothesis 
b) Psychoanalytical  theories 
III . PRENATAL  AND  PERINATAL  INSULT 
IV. FAMILY  DYNAMICS 
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I . BIOLOGICAL  THEORIES : 
a ) Genetic  hypothesis: 
Rather  than  being  the  result  of  a  single  gene  defect, mutations 
(or) polymorphisms  of  many  genes  appear  to  contribute  to  the  risk  for  
schizophrenia
3
.  Implicated  are  genes  that  regulate synaptic DA 
availability (Val{108/158} Met  polymorphism  of  catechol - O - methyl 
transferase,  neuronal  migration,  synaptogenesis  (neuregulin 1),  
(dystrobrevin  binding  protein 1 or  dysbindin, particularly with  
schizophrenia  patients  with  prominent  negative symptoms), nicotinic 
neurotransmission (Alpha 7 - receptor  polymorphisms)  and  cognition  
(disrupted - in - schizophrenia -1) 
21
. 
Increased  rates  of  genome - wide  DNA  micro duplications  termed  
copy  number  variants  are  reported  in  Schizophrenia  patients
22
. 
Epigenetic  changes,  including  disruptions  in  DNA  methylation  patterns  
are  noted  in various  brain  regions
21
.  However, this  biological  disposition  
alone  may  not  be  sufficient  to  cause  Schizophrenia  but  they  probably  
require  certain  trigger  such  as  exposure  to  prenatal  insults.  This  is  
known  as  the  Diathesis - stress  theory  of  illness  and  has  been  an  
influential  etiological  model  for  atleast  20  years
24
 . 
 
 
11 
 
Family,  Twin,  Adoption  studies : 
Family  studies: 
Family  studies  suggest  that  the  magnitude  of  the  increased  risk  
varies  not  with  the  amount  of  sharing  of  experience  but  with  the  
amount  of  sharing  of  genes.  Identical  twins  and  off springs  of  dual  
matings  have  greater  risks  than  the  first  degree  relatives . The  basic  
risk  of  schizophrenia is  1  percent  in the  population
(25, 26)
. 
Twin  studies : 
Twin  studies  provide  a  strong  evidence  that  Schizophrenia  is  
heritable . However,  because  monozygotic  twins  are  far  from  being   
100 %  concordant  for  illness (Concordance  rates  are  roughly  48 %  for  
monozygotic  twins  and  17 %  for  dizygotic  twins),  genetics  can  only  be  
the  part  of  the  explanation . Involvement  of  other  factors  is  also           
clear 
(25,26)
. 
Adoption  studies : 
The  first  adoption  study  conducted  by  Heston  suggested  that  
10.4 %  of  the  47  adopted  away  off springs  of  Schizophrenia  mothers  
were  themselves  Schizophrenic  compared  to  none  of  the  50  adopted  
away  offspring  of  matched  normal  mothers .  
In  an  important  study, Tiennari  and  colleagues   followed  a  
sample  of  Finnish  adults  who  had  been  born  to  mothers  with  
12 
 
Schizophrenia  and  then adopted  at  early  stages . It  was  found  that  even 
though  there  was  little  or  no Schizophrenia  in  the  adoptive  rearing  
families , the  at - risk  children  later   developed  significantly  higher  
levels  of  psychosis  than  found  in  similarly adopted  offspring  of  normal      
parents 
(27,28)
 .  
In  summary, the  preceding  family , twin  and  adoption   studies  
have  made  a  solid  case  for  the  genetic  etiology  of  Schizophrenia  
within  diathesis  - stress  model 
24
. 
b ) Biochemical  theories : 
 Severity  of  positive  psychotic  symptoms  in  Schizophrenic  
patients  has been  due  to  the  excessive  dopamine  release               
( Dopamine  hypothesis). 
 Also, both  the  positive  and  the  negative  symptoms  in  
Schizophrenia  has  been  thought  to  be  caused  by  increased  
Serotonin  levels (Serotonin  hypothesis)
 
 . 
  Schizophrenia  results  from  diminished  inhibitory  influences  on  
neuronal  function  which  may  be  due  to  the  hypo functioning  of  
NMDA  receptors located  on  GABA ergic inter neurons                     
(Glutamate  hypothesis) 
29 
. 
 Reduced  amounts  of  nicotinic  and  muscarinic receptors  have  
been  demonstrated  in  the  Caudate - Putamen , Hippocampus  and  
13 
 
selected  regions  of  Prefrontal  cortex  in  the  post mortem  studies  
done  in  Schizophrenia  patients . 
 Loss  of  GABA ergic  neurons  in  Hippocampus  are  also  revealed  
in   some  patients  with  Schizophrenia . 
 Anhedonia  associated  with Schizophrenia  may  be  due  to  the   
selective  neuronal  degeneration  within  the  nor epinephrine  reward  
neural  system 
20
 . 
c ) Neuropathology : 
 CT  scans  of  Schizophrenia  patients  have  consistently  revealed   
enlargement  of  lateral  and  third  ventricles  and  cortical  volume    
reduction . 
 Reduction  in  symmetry  has  been  reported  in  several  brain  areas  
including  temporal , frontal  and  occipital  lobes.   
 Within  the  Hippocampus , neurons  were  found  disorganized.  As  
Cerebellum  and  Basal ganglia  are  involved  in  the  control  of 
movements,  these  areas  are  thought  to  be  involved  in  the  patho 
physiology  of  Schizophrenia . 
 Positron  Emission  Tomography  (PET)  scan  shows  hypofrontality  
and reduced  glucose  utilisation  in  the  dominant  temporal  lobe. It  
is  also  hypothesized  that  disturbances  in   prefrontal  and  limbic  
system  function may  result  from  an  early  developmental  lesion  
of  the  dopaminergic  tracts  to  the  prefrontal  cortex . This  in  turn  
14 
 
leads  to  cognitive  impairments  and  positive  and  negative  
symptoms  in  Schizophrenia  patients.  
 Studies  using  Magnetic  Resonance  Spectroscopy  has  revealed  
that Schizophrenia  patients  had  increased  levels  of  Phospho di 
esters  and  lower  levels  of  Phospho mono esters  and inorganic  
phosphate  than  the  control  group. Also, N - acetyl  aspartate  
concentrations (marker  of  neurons  in  Hippocampus  and  frontal  
lobes) were  lower  in    Schizophrenia    patients 
20
. 
D ) Neuroanatomy : 
The  symptoms  of  Schizophrenia , the  therapeutic  effects  as  well  
as  side  effects  of  anti psychotic  effects  can  be  explained  by  the  
neuroanatomy  of  dopamine  neuronal  pathways  in  the  brain . 
1 ) Nigrostriatal  dopamine  pathway : 
This  pathway  connects  Substantia  nigra  to  the  basal  ganglia  or  
striatum, which  is  a  part  of  the  extrapyramidal  nervous  system  that  
controls  motor  function  and  movement . 
 2 ) Mesolimbic  dopamine  pathway : 
This  pathway  projects  from  the  midbrain  ventral  tegmental  area  
to  the  nucleus  accumbens.This  pathway  is  found  to  be  involved  in  
hallucinations  and  delusions  in  psychosis. 
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3 ) Mesocortical  dopamine  pathway : 
It  is  a  pathway  related  to  mesolimbic  dopamine  pathway.  It  also 
projects  from  the  midbrain  ventral  tegmental  area  but  sends  its  axons 
to  areas  of  the  prefrontal  cortex. They  may  have  a  role  in  mediating  
affective  symptoms  (ventromedial  prefrontal  cortex, VMPFC)  and  
cognitive  symptoms  (dorsolateral  prefrontal  cortex, DLPFC)  of  
Schizophrenia . 
4 ) Tubero infundibular  dopamine  pathway : 
It  is  the  fourth  dopamine  pathway  of  interest   which  projects  
from  the  hypothalamus  to  the  anterior  pituitary  gland  and  controls  
prolactin  secretion . 
5 ) The  fifth  dopamine  pathway : 
This  pathway  arises  from  multiple  sites  including  periaqueductal  
gray, ventral  mesencephalon, hypothalamic  nuclei  and  lateral  
parabrachial  nucleus, and  it  projects  to  the  thalamus.  Its  function  is  not  
currently  well known
30
 . 
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FIG 1 
DOPAMINERGIC  PATHWAYS  IN  BRAIN 
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I . PSYCHOLOGICAL  THEORIES 
a ) Stress vulnerability  hypothesis 
A genetically  vulnerable  person  develop   Schizophrenia   with  
increased  number  of  stressful  life  events  before  the  onset  (or) relapse . 
According  to  this  hypothesis,  higher  the  genetic  vulnerability  in  a 
person , lesser  the  environmental  stress  needed  to  precipitate  a  relapse . 
b ) Psychoanalytical  theories : 
Sigmund  Freud  postulated  that  the  fixations  that  occured  during  
the  development   resulted  in   Schizophrenia. Freud  postulated  that  the  
symptoms  of  Schizophrenia  were  due  to  such  defects 
23
. 
III . PRENATAL  AND  PERINATAL  INSULT : 
• Exposure  to  a  teratogen  during  gestation 
• Any  complications  during  labour  or  delivery 
• Fetal  hypoxia 
• Maternal  viral  infections 
• Prenatal  nutritional  deficiency 
Any  of  the  above  causes  may  predispose  to   Schizophrenia 
24 
. 
IV . FAMILY  DYNAMICS : 
Any  of  the  below  causes  makes  the  families  vulnerable  to  
Schizophrenia   
 Prominent  schism  between  the  parents , one  parent 
overly  close  to  a  child  of  opposite  sex 
18 
 
 Skewed  relationship  between  one  parent   and  child   
 Pseudomutual and  pseudohostile  verbal  
communication within  families 
 Increased  levels  of  expressed  emotions  in  families 
20
. 
MODE  OF  TRANSMISSION : 
Single  gene  model  and  the  multifactorial (Polygenic) model  are  
the  two  types  of  transmission  most  frequently  hypothesized . According  
to  single  gene  model,  even  if  gene  is  present , it  may  not  be  fully  
expressed  clinically ( ie,  not  everyone  who  has  the  gene  will  get  the  
disease ) 
24
. 
Gottesman  introduced  the  alternative  polygenic  multifactorial  
threshold  model  into  the  field  of  Schizophrenia . According  to  this  
model, a  complex  illness  such  as  Schizophrenia  is  the  result  of  the  
interaction  of  several  small  genes  as  well  as  other  factors  either  
environmental  or  biological 
25
. 
CLINICAL  FEATURES : 
Schizophrenia  is  characterized  by  psychotic  symptoms  as  follows. 
1 . Hallucinations : 
The  most  common  type  of  hallucination  in  Schizophrenia  are  
auditory  hallucinations. 
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2 . Delusions : 
Paranoid  delusions, Delusions  of  reference (or) Delusions  of  
control  are  more  common  in  Schizophrenia . 
3 . Passivity  phenomena : 
These  include  thought  broadcast, thought  insertion  and  thought  
withdrawal . 
4 . Disordered  thought  and  speech : 
This  may  present  as  neologisms, incoherency  in  speech (or)  
paucity  of  ideas  and  content . 
5 . Reduced  or  inappropriate  emotional  reactivity  and  lack  of  
volition:  
Schizophrenia  patients  have  incongruous  emotions, flattened  affect,  
lack  of    initiation  and  drive . 
6 . Motor  abnormalities : 
These  phenomena  may  include  posturing, mannerisms and catatonic  
immobility . 
Symptoms  in  Schizophrenia  can  be  seen  as  representing  either  an  
excess  of  normal  function  (positive  symptoms)  or  loss  (or) reduction  of  
normal  function  (negative  symptoms) 
31
. 
Positive  symptoms  -  passivity  phenomena,  hallucinations, 
delusions,  thought  disorder,  disorganized  behaviour . 
20 
 
Negative  symptoms -  Blunted  speech, poverty  of  speech and  
thought ,  withdrawal  and  impaired  volition . 
Apart  from  positive  and  negative  symptoms, numerous  studies  
also  include  cognitive  symptoms, aggressive  symptoms  and  affective  
symptoms  into  the  diagnostic  criteria 
30
. 
Aggressive  symptoms  such  as  frame  violence, verbally  abusive  
behaviours  and  assaulting  nature  can  occur  with  positive  symptoms  and  
can  be  confused  with  positive  symptoms . 
Cognitive  symptoms : 
• Problems  in  representing  and  maintaining  the  goals 
• Problems  in  focussing  and  sustaining  attention 
• Problems  in  evaluating  the  functions 
• Problems  in  monitoring  the  performance 
• Problems  in  priority  making 
• Problems  with  serial  learning 
• Impaired  verbal  fluency 
• Difficulty  in  problem  solving   
It  can  also  be  difficult  to  separate  the  symptoms  of  formal  
cognitive  dysfunction  from  the  negative  symptoms  and  from  the  
symptoms  of  affective  dysfunction. But  various  researches  are  being  
attempted  to  localize  the  specific  areas  of  brain  dysfunction  for  each  
21 
 
symptom  domain  in Schizophrenia  with  the  hope  of  developing  
treatments  for  the  often - neglected  negative, cognitive  and  affective  
symptoms  of  Schizophrenia. In  particular,  neuropsychological  assessment  
batteries  are  being  developed  to  quantify  cognitive  symptoms, in  order  
to  detect  cognitive  improvement  after  treatment  with  a  number  of  
novel  psychotropic  drugs  currently  being  tested 
30
 . 
LOCALIZATION  OF  SYMPTOM  DOMAINS : 
The  different  symptom  domains  of  Schizophrenia  are  
hypothesized  to  be  regulated  by  unique  brain  regions  . 
 Positive  symptoms  of  Schizophrenia  are  hypothetically  
modulated  by  malfunctioning  mesolimbic  circuits. 
 Negative  symptoms  are  hypothetically  linked  to  malfunctioning 
mesocortical  circuits  and  may  also involve  mesolimbic  regions  
such  as  the  nucleus  accumbens  which  is  a  part  of  brain's  
reward  circuitry  and  thus  plays  a  role  in  motivation . Nucleus  
accumbens  may  also  be  involved  in  the  increased  rate  of  
substance  use  and  abuse  seen  in  patients  with  Schizophrenia . 
 Affective  symptoms  are  associated  with  the  ventromedial  
prefrontal  cortex. 
 Aggressive  symptoms  are  associated with  abnormal  processing 
of  information  in  amygdala  and  the  orbito frontal  cortex . 
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 Cognitive  symptoms  are  associated  with  problematic  
information  processing  in  the  dorso lateral  prefrontal  cortex. 
Although  there  is  an  overlap  in  function  among  different  brain  
regions, understanding  the  brain  regions  predominantly  involved  in  
specific  symptoms  can  aid  in  the  customization  of treatment  to  
particular  symptom  profile  of  each  individual  patient  with  
Schizophrenia 
30
 . 
DIAGNOSTIC  SUBTYPES : 
Schizophrenia  can  be  classified  into  several  subtypes.  
Paranoid  Schizophrenia : 
The  characteristic  feature  of  Paranoid  Schizophrenia  is  the  
presence  of  frequent  auditory  hallucinations  and  either  one  or  more  
delusions . No  prominent  disturbances  of  affect, volition, speech, and / or  
motor  behaviour. 
Disorganized  ( or ) Hebephrenic  type : 
The  term  Hebephrenia  was  first  described  by  Ewald  Hecker. The  
characteristic  features  of  this  subtype  are  incoherence , thought  disorder  
and  severe  loosening  of  association. Presence  of  insidious  onset, 
continuous  course, poor  premorbid  function  and  a  poor  prognosis  are  
the  distinctive  features  of  this  subtype. 
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Catatonic  type : 
The  criteria  for  the  catatonic  subtype  requires   two  to  five  of  the  
following  characteristic  symptoms . 
• Immobility [ ( Stupor ) or ( catalepsy ) ] 
• Excessive  purposeless  motor  activity 
• Negativity 
• Peculiar  movements [ Posturing , stereotypies , 
mannerisms , ( or ) grimacing ] 
• Echolalia  ( or ) echopraxia 
Undifferentiated  type : 
This  category  is  defined  to  include  patients  who  meet  the  
criteria  for  Schizophrenia  but  cannot  be  clearly  classified. The  diagnosis  
of  this  subtype  is  through  the  exclusion  of  other  subtypes . 
Residual  type : 
This  diagnostic  criteria  is  used  for  patients  who  have  had  atleast  
one  psychotic  episode  in  the  past  and  have  met  the  criteria  for  
schizophrenia  before  but  no  longer  have  psychotic  symptoms . 
 Simple  type (Simple  deteriorative  disorder ) : 
This  category  is  not  included  in  DSM - IV - TR criteria  but  still  
exists  in  ICD - 10  criteria. The  diagnosis  is  solely  based  on  deficit    
(or) negative  symptoms. Psychotic  symptoms  are  not  necessary  for  the  
diagnosis. 
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The  catatonic  and  hebephrenic  subtypes  of Schizophrenia  together  
have  been  called  as  nuclear  Schizophrenia  as  they  present  with  typical  
symptomatology  of  Schizophrenia  and  can  most  frequently  result  in  
personality  deterioration  over  time (especially  if  chronic)
11
.  
Other  subtypes 
20
 : 
Bouffee  Delirante ( Acute  delusional  psychosis ) 
• Latent 
• Oneiroid 
• Paraphrenia 
• Pseudoneurotic  Schizophrenia 
• Post  psychotic  depressive  disorder  of  Schizophrenia 
• Early  onset  Schizophrenia 
• Late  onset  Schizophrenia 
• Deficit  Schizophrenia 
COURSE  AND  PROGNOSIS : 
Course : 
The  classical  course  of   Schizophrenia  consists  of   remissions  and  
exacerbations . A  patient  recovers  and  functions  normally  after  the  first  
psychotic  episode  but  the  patients  usually  relapse. The  patient's  baseline  
functioning  deteriorates  after  every  episode  of  psychosis. Vulnerability  
to  stress  is  lifelong  in  patients  with  schizophrenia. Positive  symptoms  
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become  less  severe  with  time. However  the  negative  or  symptoms  
increase  in  severity 
31
. 
Prognosis : 
 Only  about  10  to  20 %  of  patients   have  a  good  outcome  after  
the  first  psychiatric  hospitalization  for  Schizophrenia  . 
 More  than  50 %  of  patients  have  a  poor  outcome  such  as   
symptom  exacerbation, repeated  hospitalization and  suicide  
attempts . 
 About  40  to  60 %  of  patients  remain  impaired  by  the  disorder  
throughout  the  life  and  20  to  30% of  patients  continue  to  
experience  symptoms  moderately 
31
 . 
                                                TABLE 2  
                                             PROGNOSIS 
           Good prognosis            Bad  prognosis 
                      Late  onset                 Young  onset 
Obvious  precipitating  factors      No  precipitating  factors 
Married       Single/divorced/widowed 
Good  support  systems         Poor  support  systems 
Positive  symptoms           Negative  symptoms 
 
  
 
 
26 
 
  DIFFERENTIAL  DIAGNOSIS 
31
 : 
 Organic  mental  disorders  with  Schizophrenia - like  symptoms  
may  be  seen  in  Huntington's  chorea (early  stage), 
omocystinuria , Acute  intermittent  porphyria, Wilson's  disease, 
Haemochromatosis 
 Secondary  psychotic  disorders 
 Other  psychotic  disorder 
• Schizophreniform  disorder 
• Brief  psychotic  disorder 
• Schizo affective  disorder 
• Delusional  disorder 
 Mood  disorders 
• Unipolar 
• Bipolar 
 Personality  disorders 
• Schizotypal 
• Schizoid 
• Borderline  personality  disorder 
 Malingering 
 Factitious  disorders . 
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DIAGNOSIS : 
Diagnosis 
20
  is  mainly  by 
   I )  Mental  status  examination 
   II )  Certain  psychological  tests 
• Halstead - Reitan  battery 
• Luria - Nebraska  battery 
III ) Intelligent  tests 
IV ) Projective  tests 
• Rorschach  test 
• Thermatic  appreciation  test 
V ) Personality  tests 
• Minnesota  Multiphasic  Personality  Inventory 
MANAGEMENT: 
Management  of  Schizophrenia  includes  pharmacological, physical  
methods 
11
  and  psychosocial  interventions 
20
 . 
1 ) Pharmacotherapy : 
This  includes  typical  and  atypical  antipsychotics . 
2 ) Physical  methods : 
 Electroconvulsive  therapy 
 Psychosurgery 
3 ) Psychosocial  interventions : 
 Social  skills  training 
28 
 
 Family  oriented  therapy 
 Cognitive  behavioral  therapy 
  Vocational  therapy   
I  .  PHARMACOTHERAPY : 
The  drugs  currently  used  to  treat  Schizophrenia  are  classified as 
either  typical (also  referred  to  as first  generation) (or) atypical  (second  
generation)  antipsychotics. 
Typical  antipsychotics : 
Henri  Laborit , surgeon  in  Paris , in  the  early  1950 's  discovered  
the  " calming " effect   of  Chlorpromazine  in  Schizophrenia  patients . 
In  1963, Carlsson  and  Linquist  found  an  association  between  the  
Phenothiazine's  therapeutic  effect  and  dopamine  inhibition.  This  resulted  
in  the  dopamine  hypothesis  of  Schizophrenia. It  postulated  that  
psychosis  was  due  to  an  increase  in  dopaminergic  function  in  the  
brain . Neuroleptics  alleviate  the  symptoms  of  schizophrenia  by  
blocking  the  dopamine  receptors . 
During  the  late  1970's, it  was  shown  that  the  action  of  
neuroleptics  was  better  correlated  with  their  effect  of  blocking  the  
dopamine  receptors  in  vitro . 
In  1979,  Kebabian  and  Calne  classified  dopamine receptors  into  
two  specific  types  and  correlated  the  potency  of    Phenothiazine  
neuroleptics  and  Haloperidol  and  their  affinity  for  D 2  receptors . 
29 
 
After  the  introduction  of  molecular  cloning  techniques, five  
distinct  subtypes  of  the  dopamine  receptor   have  been  discovered  and  
they  are  broadly  classified  into  those  resembling  the  original  D 1  
receptor ( D 1  & D 5 )  and  those  resembling  the  D 2  receptor (D 2 , D 3  &   
D 4 ) 
32
 . 
CLASSIFICATION (TYPICAL  ANTIPSYCHOTICS ) : 
A ) Phenothiazines : 
 Aliphatic  derivative : Chlorpromazine , Trifluopromazine 
 Piperidine  derivative : Thioridazine . 
 Piperazine derivative: Perphenazine, Fluphenazine,   
Thioproperazine 
B ) Butyrophenones : 
Haloperidol , Trifluperidol , Droperidol , Penfluridol . 
c ) Thioxanthines : 
Chlorprothixine , Thiothixine , Flupenthixol . 
d ) Miscellaneous : 
          Pimozide , Molindone , Loxapine 
3
 . 
Typical  antipsychotics  have  potent  dopamine  D 2  receptor  
blocking  property  and  to  a lesser  extent , 5 - HT  receptor  blockade. They  
are  also  called  neuroleptic  drugs. Phenothiazines  and  Thioxanthines  also  
block  D 1 , D 3  & D 4  receptors. 
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Blockade  of  dopamine  receptors , 
 In  the  limbic  system  leads  to  antipsychotic  effect . 
 In  the  CTZ  leads  to  antiemetic  effect . 
 In  the  corpus  striatum  leads  to  extrapyramidal  side  effects. 
 including  Parkinson 's  disease . 
 In  the  anterior  pituitary  leads  to  increased  prolactin  level  i.e, 
 Hyperprolactinaemia . 
High  efficacy (low  dose)  neuroleptics  such  as  Haloperidol , 
Fluphenazine  and  Trifluoperazine  with  more  specific  action  cause  EPS  
more  often . This  is  because  the  low  dose  neuroleptics  are more  
selective  in  binding  to  D 2  receptors . 
Low  efficacy ( high  dose ) drugs  such  as  Chlorpromazine have  
high affinities  for  H1 , M1 , and  α1 receptors  that  cause  many  undesirable  
effects  ( sedation , anticholinergic  properties , orthostasis )  but  have  lesser  
chances  of  EPS
 33
 . 
ATYPICAL  ANTIPSYCHOTICS : 
An  important  breakthrough  occured  in  the  development  of  novel  
neuroleptics  25  years  ago. Clozapine  was  discovered  and it was  novel  
because  it  caused  attenuation  of  both  the  positive  and  negative  
symptoms  of  Schizophrenia  without  causing  EPS  (or) elevating  serum  
prolactin concentrations 
32
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CLASSIFICATION ( ATYPICAL  ANTIPSYCHOTICS ) : 
• Dibenzodiazepines : Clozapine . 
• Thienobenzodiazepines : Olanzapine . 
• Dibenzothiazepines : Quetiapine . 
• Benzamide : Sulpiride , Amisulpiride . 
• Benzisoxazole : Risperidone . 
• Indole  derivative : Sertindole . 
• Others : Aripiprazole , Ziprasidone , Asenapine 
3
 . 
These  drugs  block  5 - HT2A  receptors  more  than   D2  receptors 
29
. 
They  also  act  as  partial  agonists  at  the  5 - HT1A   receptor. They  are  
antagonistic  at  5 - HT6  (or)  5 - HT7  receptor 
 29
. 
Of  these  drugs , Risperidone is  similar  to  high  potency first  
generation  antipsychotics . It  acts  by  blocking  D2  receptors  in the  
mesolimbic  area  and  so  the  positive  symptoms  are  improved . It  blocks  
5HT2  receptors  in  the  cortex and  so  the  negative  symptoms  are  
improved. It  is   antagonistic  at  D1 , D4, histamine , Ach  and  α1 receptors
34
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                                                FIG 2  
                        STRUCTURE  OF  RISPERIDONE 
 
 
 
 
 
 
 
 
 
 
DEPOT  PREPARATIONS  : 
Depot  preparations  have  been  developed  which  have  long  
duration  of  action, convenient  and  increase  patient  compliance .  The  
preparations  available  are : 
 Fluphenazine  decanoate  administered  every  2 - 4  weeks 
 Haloperidol  decanoate  administered  every  2 - 4  weeks 
 Risperidone  in  the  form  of  carbohydrate  microspheres  
administered  every  2 - 3  weeks 
 Flupenthixol  decanoate  administered  every  2 - 4  weeks 
33 
 
 Zuclopenthixol  acetate  or  decanoate  administered  every  1 - 4  
weeks
35 .
 
PHARMACOKINETICS : 
Most  of  the  antipsychotic  drugs  are  incompletely  absorbed . They  
undergo  significant  first  pass  metabolism . They  are lipid  soluble.  They  
are  92 - 99 %  protein  bound . They  have  large volumes  of  distribution . 
They  generally  have  a   longer  duration  of  action . Most  antipsychotics  
are  completely  metabolised  by  oxidation (or)    demethylation 
29
 . 
ADVERSE  EFFECTS : 
ADVERSE  EFFECTS  RELATED  TO  MONOAMINE  
RECEPTORS: 
Dopamine  D2  receptor : 
All  antipsychotic  agents  possess  D2   antagonist  properties  with the  
exception  of  the  D2 partial  agonist, Aripiprazole. The  strength  of  this 
antagonism  determines  the  likelihood  for  EPS, akathisia, 
hyperprolactinemia  and  long  term  tardive  dyskinesia  risk . 
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TABLE 3 : NEUROLOGICAL  SIDE  EFFECTS  OF  
ANTIPSYCHOTIC  DRUGS 
REACTION FEATURES TIME OF 
ONSET 
& RISK 
INFO 
PROPOSED 
MECHANISM 
TREATMENT 
Acute 
Dystonia 
Spasm  of  
muscles  of  face 
, tongue , neck  &  
back . 
Time : 
1 - 5 days 
Young , 
Antipsych
otic 
Naive  
patients  at  
high  risk 
 Dopamine 
Antagonism 
Diphenhydra
mine  25-50 
mg  IM , or  
benztropine 
1-2 mg  IM . 
Akathisia Subjective and 
objective 
restlessness; 
not anxiety  or 
“agitation” 
Time: 5-
60 days 
Unknown Reduce dose 
or change 
drug 
;Clonazepam, 
Propranolol  
more 
effective  
than  anti - 
parkinsonian  
drugs . 
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Parkinsonism Bradykinesia, 
Rigidity 
,Variable  
tremor,mask 
facies, Shuffling  
gait 
Time : 5 - 
30 days . 
Elderly  at  
great  risk 
DA  antagonism Dose  
reduction ; 
Change  
medication : 
Amantadine 
Neuroleptic 
Malignant 
Syndrome 
Extreme  rigidity 
, fever, Unstable  
BP, 
Myoglobinemia ; 
It  can  be  fatal . 
Time : 
weeks  to  
months . 
Can  
persist  for  
days  after  
stopping 
antipsycho
tic 
Dopamine  
antagonism 
Stop  
antipsychotic  
immediately ; 
Supportive  
care : 
Dantrolene  
& 
Bromocriptin
e 
 
Perioral  
tremor 
("Rabbit 
syndrome ") 
Perioral  tremor  ( 
may be  a late  
variant  of  
parkinsonism) 
 
Time : 
Months  or  
years  of  
treatment 
Unknown Amantadine 
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Tardive  
dyskinesia 
Orofacial  
dyskinesia 
Time : 
Months  or  
years  of  
treatment . 
Elderly  at  
5 fold  risk 
. 
 
Postsynaptic  
DA  receptor  
supersensitivity 
, upregulation 
May  be  
reversible  
with  early  
recognition  
&drug  
discontinuati
on . 
 
H 1  receptors : 
Central  antagonism  of  H 1  receptors  is  associated  with  two  major  
adverse  effects : Sedation  and  weight  gain  via  appetite  stimulation . 
Appetite  stimulation  is  the  primary  mechanism  involved , with  little  
evidence  to  suggest  that  decreased  activity (due  to  sedation ) is  a  main  
contributor  of  antipsychotic - related  weight  gain 
36
 .  
The  low  potency  Phenothiazine, Chlorpromazine  and  atypical  
antipsychotic  drugs  Olanzapine  and  Clozapine  are  the  agents  of  highest  
risk  with  mean  annual  weight  gain  of  13 kgs . High-potency  typical 
antipsychotic drugs (e.g., haloperidol, fluphenazine) , and newer  atypical  
antipsychotics   Asenapine , Ziprasidone , and Aripiprazole  are associated  
with mean annual weight gains < 2 kg in schizophrenia patients  with mean  
gains of 2.5-3 kg noted for iloperidone , risperidone,  and quetiapine 
37
 . 
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M 1  receptors : 
 Clozapine , Low  potency  Phenothiazines - Significant  anti - 
cholinergic  activity . 
 Risperidone , Paliperidone , Asenapine , Iloperidone , Ziprasidone , 
Aripiprazole - No  appreciable  anti - cholinergic  effect . 
 Quetiapine - modest  muscarinic  affinity  but  its  active  metabolite , 
Norquetiapine  is  likely  responsible  for  anti - cholinergic     
complaints 
38
  .  
α 1   receptors : 
 Risk  of  orthostatic  hypotension . 
 Low  potency  typical  agents - Greater  risk  for  orthostasis . 
ADVERSE  EFFECTS  NOT  RELATED  TO  MONOAMINE  
RECEPTORS : 
Adverse  metabolic  effects : 
 Atypical  antipsychotics  are  associated  with  glucose  dysregulation . 
 Certain  atypical  antipsychotics  and  low  potency  conventional 
agents  have  been  associated  with  hyperlipidemia . 
Adverse  cardiac  effects : 
 Thioridazine, Mesoridazine, Pimozide, i.m Droperidol & i.v 
Haloperidol  are  reported  to  cause  Torsades  de  pointes  and 
subsequent  ventricular  arrythmias  due  to  inhibition  of  cardiac  K
+
 
channels . 
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Other  adverse  effects : 
 Seizure  risk - more  common  with  Carbamazepine  and  Clozapine . 
 Clozapine  induced  agranulocytosis  is  immune  mediated  and  those 
patients  should  not  be  rechallenged . 
 Thioridazine  causes  pigmentary  retinopathy  at  daily  doses  >  800 
mg / day . 
 Low - potency  phenothiazines  are  associated  with  the  development  
of  photosensitivity 
3
 . 
CHOICE  OF  ANTIPSYCHOTICS : 
Since  the  early  1990's , Second  generation  antipsychotics  have  
been  used  widely  with  the  belief  that  these  agents  were  more  
effective, better  tolerated  and  ultimately  more  cost - effective  than  first  
generation antipsychotics . Only  limited  studies  comparing  first  and  
second  generation  existed . To  address  this  knowledge  gap , the  National  
Institute  of  Mental  Health ( NIMH )  sponsored  the  Clinical  
Antipsychotic  Trials  of  Intervention  Effectiveness ( CATIE ) study 
39
 . 
CATIE  study  was  designed  to  compare  the  effectiveness  of four  
second  generation  antipsychotics  (Olanzapine , Quetiapine , Risperidone , 
Ziprasidone)  and  a  representative  first  generation antipsychotic                 
(Perphenazine)  in  " real  world " Schizophrenia  patients . Phase  II  CATIE  
study  suggested  that  Olanzapine  and  Quetiapine  were more  effective  
39 
 
than  Risperidone , in  patients  who  failed  to  respond  to Perphenazine 
40
 . 
However , the  CATIE  cost - effectiveness  analysis  found Perphenazine  to  
be  less  costly  and  similarly  effective  than  each  of  the atypical  
antipsychotics 
41
 . 
Similarly  to  the  NIMH - sponsored  CATIE  study , the  United  
Kingdom's  National  Health  Service  funded  the  Cost  Utility  of  the  
Latest  Antipsychotic  drugs  in  Schizophrenia  study ( CUtLASS ) This  
study  found  no  difference  between  first  and  second  generation  
antipsychotics  in  terms  of  quality  of  life . 
 Clozapine  should  be  considered  for  patients  who  have  failed  to  
respond  to  other  second  generation  medications  . 
 Long  Acting  Injectables ( LAI )  may  be  considered  for  patients  
with  poor  adherence . 
 First  generation  agents  clearly  have  the  highest  risk  of  EPS  and  
tardive  dyskinesia 
42
 . 
 Risperidone  and  the  newly  available  Paliperidone  tend  to  increase  
serum  prolactin  levels  and  tend  to  cause  EPS  at  higher  doses . 
 Although  weight  gain  and  metabolic  disturbances  are  associated  
with all  of  the  second  generation  agents  ( with  the  possible  
exception  of Ziprasidone  and  Aripiprazole ) . Olanzapine  and  
Clozapine  appear  to  have  the  highest  likelihood  of  causing  these  
side  effects 
43
 . 
40 
 
 Sedation  is  commonly  observed  in  patients  receiving  Quetiapine , 
Olanzapine  and  Clozapine . 
 Both  Ziprasidone  and  Paliperidone  carry  product  labeling  for  QTc 
prolongation  and  should  be  used  cautiously  in  patients  at  risk  
for  QTc  prolongation 
1
 . 
 Risperidone  and  Aripiprazole  is  FDA  approved  for  irritability 
associated  with  autism  in  child  and  adolescent  patients  aged  5 - 
16
 
 years . 
 Antipsychotics  carry  pregnancy  class  B ( or ) class C  warnings . 
 Medications  with  significant  anti cholinergic  property  should  be 
particularly  avoided  in  elderly  patients . 
 α 1  antagonists  also  should  be  avoided  in  elderly  patients  with  
poor vasomotor  tone 
3
 . 
 Finally , Clozapine , because  of  its  side  effects  of  granulocytosis , 
seizures  and  myocarditis  is  generally  reserved  for  patients  with  
treatment  resistant  illness  or  suicidality 
1
 . 
MANAGEMENT  OF  VARIOUS  CONDITIONS : 
ACUTE  PSYCHOSIS : 
Acute  phase  is  characterized  by  psychotic  symptoms  and  often  
by  agitation  and  lasts  from  4 to 8  weeks 
6 
. This  phase  is   managed  
with  the  use  of  high  potency  first  generation  antipsychotics  either  
41 
 
alone (or)  in  conjunction  with  a  Benzodiazepine  (such  as  Lorazepam )  
and / (or)  an  anticholinergic  drug (such  as  Benztropine).  
FIRST  EPISODE  PSYCHOSIS : 
Because  of  the  most  favourable  neurological  side - effect  profile  
mainly  the  reduced  risks  of  adverse  neurological  events , second  
generation  antipsychotics  are  often  considered  for  the  initial  treatment  
of  first  episode  psychosis 
1
. 
MAINTENANCE  TREATMENT : 
The  major  goals  of  maintenance  treatment  are  prevention  of  
relapse  and  improvement  in  psychosocial  and  vocational  function . 
Several  studies  have  demonstrated  that  higher  rates  of  relapse  are  
associated  with  medication  discontinuation 
( 44,45,46)
 . Even  after  recovery  
from  acute  symptoms, this  phase  of  treatment  lasts  for  6  months 
6
 . 
All  available  atypical  antipsychotics  have  been granted  U. S FDA  
approval  for  the  maintenance  treatment  of Schizophrenia . Moreover , 
some  evidence  suggests  that  atypical antipsychotics  may  be  more  
effective  than  conventional  agents  in forestalling  relapse 
(47,48)
 . 
TREATMENT - RESISTANT  SCHIZOPHRENIA : 
For  research  purposes , Kane  et  al  operationally  defined  treatment  
resistance  as 
42 
 
1) Lack  of  significant  response  to  atleast  three  adequate  trials  of 
neuroleptics  from  atleast  two  different  chemical  classes  in  the  
past  five  years . 
2) Persistently  poor  social  and  occupational  functioning  
(49,50,51) 
. 
Most  of  the  available  data  suggest  that  Clozapine  is  the  most  
effective  drug  for  treatment  resistant  Schizophrenia 
1
 . 
II .   PHYSICAL  METHODS : 
1 ) Electroconvulsive  therapy ( ECT ) : 
ECT  is  a  biological  therapy , wherein  seizures  are  induced  under  
medical  supervision  by  passing  electric  current  across  the  scalp . ECT  
helps  to  control  the  excitement , violence  & aggression  in  acute  
Schizophrenia  in  usually  3  sittings . A  combination  of  ECT  and  
neuroleptics  have  better  effects  than  ECT  alone(or) neuroleptics alone 
52
.  
2 ) Psychosurgery : 
Psychosurgery  is  defined  as  a  surgical  intervention  to  disconnect  
fibres  connecting  one  part  of  brain  with  another  with  the  intent  of  
modifying  the  behavior , thought (or) mood  disturbances  for  which  there  
is  no  organic  pathology 
23
 . 
It  is  not  considered  an  appropriate  treatment  nowadays . It  is 
practiced  only  for  severe , intractable  cases 
53
.  
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III  . PSYCHOSOCIAL  INTERVENTIONS : 
Psychosocial  therapies  are  intended  to  increase  the  social  
abilities, interpersonal  communication , self - sufficiency  and  practical  
skills  in    patients  with  Schizophrenia . 
A ) Social  skills  training : 
Also  referred  to  as  behavioral  skills  therapy . Videotapes , role 
playing , homework  assignments  for  the  specific  skills  are  currently  
used  in  therapy. 
B ) Family  oriented  therapies : 
The  aim  of  this  therapy  is  to  identify  and  avoid  the  potentially  
troublesome  situation  in  family  and  if  it  emerges , resolve  the  problem  
quickly . 
C ) Cognitive  behavioral  therapy : 
CBT  has  been  devised  to  improve  cognitive  distortions , decrease  
the  distractability  and  correct  the  errors  in  judgements  among  
schizophrenia  patients . 
D ) Vocational  therapy : 
Various   methods  are  used  to  help  patients  regain  their  old  skills 
(or) develop  new  ones . These  include  job  clubs , sheltered  workshops  
and  transitional  employment  programs 
20
 . 
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EMERGING  TARGETS  AND  THERAPEUTICS  IN   
SCHIZOPHRENIA :   
Several  new  molecular  targets  are  being  actively  pursued. They  
are  as  follows . 
a ) NMDA  agonists : 
 Agents  like  glycine 
54
 , serine 
55
  and  D - Cycloserine 
56
  bind  to  the   
allosteric  facilitator  glycine  binding  site  to  increase   efficiency  at  
the  NMDA  receptor . 
 mGlu 2 / 3  receptor  agonist  LY2140023  proved  effective  in  phase  
II  Schizophrenia  trial 
57
 . 
 Glycine  is  a  co - transmitter  at  glutamate  receptors. Gly T1  
inhibitor  SSR 504734  was   effective  in  blocking  PCP - induced  
CNS  metabolic  changes  in  rats 
3
 .  
b ) Muscarinic  agents : 
 M1  and  M2  muscarinic  receptor  modulators  have  passed  several  
preclinical  antipsychotic  tests 
58
 . 
 M1 / M4  agonist  Xanomeline  has  precognitive  and  antipsychotic  
affects  in Schizophrenia  trials 
59
 .  
c ) Nicotinic  agents : 
Agonists  at  α 7 
(60)
  and  α 4 β 2 
(61)
  nicotinic  receptors  are  under  
trial  as  Schizophrenics  have  deficits  in  nicotinic  Ach  receptor  function . 
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d ) Phosphodiesterase ( PDE )  inhibitors : 
PDE  inhibitors  that  degrade  cAMP  has  met  the  criteria  for  
antipsychotic  agents  in  preclinical  studies 
(62,63)
 . 
e ) Erb  B  antagonists : 
As  Neuregulin (NRG)  and  its  receptor  erb B  are    implicated  in  
the  pathophysiology  of  Schizophrenia , erb B  antagonists  are  tried  as  a  
novel  approach  in  the  treatment  of  Schizophrenia 
(64,65,66)
. 
f ) Others : 
               Lurasidone  is  a  novel  5HT / DA  antagonist  under  trial 
3
 . 
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                                 METABOLIC SYNDROME: 
Metabolic  syndrome  (Met S)  is  a  complex  disorder  considered  a  
worldwide Epidemic 
67
. Although  Hims worth   reported  insulin  resistance  
in  diabetes  in  1939
68
,  insulin  resistance  syndrome  as  a  separate  entity  
was  reported  in  1988  by  Reaven . It  included  hyperglycemia , insulin 
resistance , hypertension , high  VLDL  triglycerides  and  low  HDL 
cholesterol  and  was  also  called  as  syndrome - X 
69
. Surprisingly  he  
missed  visceral  obesity  from  the  definition  and  later  added  it  as  a  
crucial abnormality
70
 . 
Since  then, many  international  organizations  and  expert groups , 
such as  the  World  Health  Organization  (WHO), the  European  Group  
for  the study  of   Insulin  Resistance  (EGIR) , the  National  Cholesterol  
Education Program  Adult  Treatment  Panel  III (NCEP : ATPIII) , the  
American Association  of  Clinical  Endocrinology (AACE) , the  
International  Diabetes Federation (IDF), and  the  American  Heart  
Association / National  Heart , Lung , and  Blood  Institute (AHA/NHLBI) , 
have  attempted  to  incorporate  all  the different  parameters  used  to  
define  Met S 
67
 . The  first  attempt  was  made  in 1998  by  the  WHO , 
which  proposed  the  following  criteria  for  metabolic  syndrome . 
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WHO CLINICAL CRITERIA FOR METABOLIC SYNDROME .  
Insulin  resistance , identified  by  one  of  the  following: 
 Impaired  fasting  glucose  
 Type  2  diabetes 
 Impaired  glucose  tolerance 
Plus  any  two  of  the  following: 
 Plasma  triglycerides  ≥ 1.7  mmol/L  
 Antihypertensive  medication  and / or  high  blood  pressure  ( ≥140 
mm Hg  systolic  or  ≥ 90 mm Hg  diastolic ) 
 BMI  > 30 kg / m
2
 and / or  waist : hip  ratio  > 0.9  in  men ,  > 0.85  
in  women  
 Urinary  albumin  excretion  rate  ≥ 20 µg / min  or  albumin : 
creatinine  
 ratio  ≥ 3.4  mg / mmol 
71
 
 HDL  cholesterol  < 0.9  mmol / L in  men  or  < 1.0  mmol / L  in 
women 
Some  studies  have  suggested  increased  levels  of  inflammatory  
markers  such  as, C reactive  protein (CRP)  as  an  important  predictor  of  
cardiovascular  risk  in  patients  with  metabolic  syndrome
72
.  Among  the  
drugs , HAART  therapy  and  atypical  antipsychotics  carry  high  risk  for  
metabolic  syndrome . 
48 
 
The  metabolic  syndrome  appears  to  affect around 10 to 25 percent  
of  adult  population  worldwide
73
 . In  India , both  insulin  resistance  and  
the  metabolic  Syndrome  has  wide  prevalence
74
. The  Jaipur  Heart Watch  
Studies  have  reported  the  prevalence  of  metabolic  syndrome  among  
urban  Indians  as  18.4%  in  men  and  30.9%  in  women  and  24.9% 
overall
75
. The  age - related  prevalence  seems  to  be  escalating  in  both  
men  and women
70
 . 
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Figure 3: Schematic  image  of  the  conditions  implicated  in  the  patho 
physiology  of  Metabolic  syndrome  and  the  potential  interactions
67
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METABOLIC  SYNDROME  AND  ATYPICAL  ANTIPSYCHOTICS  
Possible  mechanisms: 
1) Weight  regulation  is  a  complex  balance  of  energy  intake , storage 
and  expenditure  driven  by  both  endocrine  mechanisms  and  central  
nervous  system . 
  a ) CNS  system  drives : 
 Satiety - Desire  to  limit  further  food  intake  after                       
completing  a  satisfying  meal . 
 Appetite - Desire  for  food (or) drink       
 Craving - An  intense  desire (or) longing .   
b ) Endocrine  actions : 
 Energy  utilisation 
 Metabolism 
c ) Imbalance  between  energy  ingestion  and  energy  expenditure leads  to  
weight  gain . 
 II ) Receptor  mediation  of  neurotransmitters  and  hormones : 
 a ) 5 HT2c  receptor :       
 Decreased  food  consumption   occurs  either  due  to  increased  
serotonin  concentrations  in  the  synaptic  cleft  (or)  due  to  direct  
activation  of  5HT2c  receptor  .  
 Antagonistic  effect  at  5 HT2c  receptor  induces  opposite  effect . 
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b ) Histamine - 1 receptor : 
 Regulates  arousal  and  appetite . 
 H 1  receptor  antagonism  causes  increase  in  appetite  and  weight   
gain . 
 Binding  studies  reveal  that  sedation  and  weight  gain  are  directly  
proportional  to  the  ability  of  the  agent  to  block  H 1  receptors . 
TABLE 4 
RELATIVE  RECEPTOR  BINDING  AFFINITIES  OF  ATYPICAL 
ANTIPSYCHOTICS 
80
 
Receptor Risperidone Olanzapine Quetiapine Clozapine 
H 1 
Histaminergic 
     
      ++ 
    
   ++++ 
   
    ++++ 
   
  ++++ 
c ) Leptin : 
 Leptin  is  a  member  of  IL - 6  family . 
 It  is secreted  by  white  adipose  cells . 
 Insulin  secretion  is  regulated  by  leptin . 
 Energy  metabolism  in  skeletal  muscle and  fat  cells  is  regulated  by  
leptin. 
 Leptin  resistance  is  the  obesity  associated  with  malfunctioning  
lepin  receptors. 
d ) Poor  self  care 
e ) Sedentary  lifestyle 
52 
 
f ) Unhealthy  dietary  habits 
( 76,77,78,79)
  
Morbidity  and  mortality : 
 The  prevalence  of  metabolic  syndrome  in  adults   with  
schizophrenia  varies  between  20 % and  60 % .This  is  actually  
twice  that  of  the  normal  healthy  population 
81
 .  
 The  prevalence  of  metabolic  syndrome  in  patients  without  
glucose  abnormalities  was  17.5 % ( ATP - III  criteria ) and  21.5 % 
( IDF) 
82
. 
 Also, it  has  been  found  that  the  prevalence  of  dyslipidemia,  
hypertension , obesity  and  type  II  diabetes  mellitus  is  around  1.5  
to  2  times  greater  in  individuals  with  schizophrenia  compared  
with  the  general  population 
83
 . 
 Cardiovascular  mortality  accounts  for  a  total  of  34 %  of  deaths 
among  the  male  patients  and  31 %  of  deaths  among  the  female  
patients  with  schizophrenia 
(84,85)
 . 
MONITORING  PROTOCOL : 
Appropriate  baseline  screening  and  ongoing  monitoring  are  
essential  in patients  taking  atypical  antipsychotic  drugs . 
 Baseline  monitoring 
The  baseline  screening  should  be  done  before  or  soon  after  the  
initiation  of  any  antipsychotic  medication . These  include 
53 
 
 Personal  and  family  history  of  obesity , diabetes , dyslipidemia , 
hypertension , or  cardiovascular  disease  
 Waist  circumference (at  the  level  of  the  umbilicus ) 
  Weight  and  height ( so  that  BMI  can  be  calculated )  
 Fasting  lipid  profile 
  Blood  pressure 
  Fasting  plasma  glucose 
Follow  up  monitoring : 
 Weight  must  be  reassessed  at  4 , 8 , and  12 weeks  of  initiating  
the  SGA  therapy  and  thereafter  every  3  months  at  the  time  of  
routine   visits . 
 Waist  circumference  to  be  assessed  annually . 
 Blood  pressure  and  fasting  blood  glucose  levels  should  be  
assessed  at 12  weeks  and  after  one  year  of  initiation  of  therapy  
and  fasting  lipid  profile  at  12  weeks  and  5  yrs 
76
  . 
MANAGEMENT  OF  METABOLIC  SYNDROME : 
I. Pharmacological  strategies 
II. Non - pharmacological  interventions . 
I . Pharmacological  strategies : 
A. Switching  the  medication 
B. Medication  to  effect  weight loss  or  prevent  weight  gain 
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A )  Switching  the  medication : 
Switching  from  an  antipsychotic  medication  to  another   has  
significant  effect  on  metabolic  parameters  and  body  weight . Results  of  
CATIE  trials  suggest  that  switching  to  an  antipsychotic  drug  with  a  
neutral  metabolic  profile  provide  a  beneficial  weight  change .There  was  
a  significant  reduction  in  body  weight, waist circumference and  blood  
pressure  when  Risperidone  was  substituted  for  Olanzapine 
86
 . 
B ) Medication  to  effect  weight loss  or  prevent  weight  gain : 
Many controlled  clinical  trials  have  shown  that  obesity  drugs  in  
combination  with  lifestyle   therapy   provide  modest  efficacy 
87
 . Phenyl 
propanolamine 
88
  and  D - Fenfluramine 
89
 are removed  from  the  market  
because  of  adverse  effects . Rimonabant  is  an  anorectic  anti - obesity  
drug  that  has  been  withdrawn  from  the  market  due  to  serious  adverse  
effects . 
a ) Nizatidine :   
Nizatidine  is  a  histamine  H2  receptor  antagonist . Nizatidine       
(150 mg twice  daily) was  tried  for  Olanzapine - induced  weight  gain . 
Nizatidine  showed  weight  loss  compared  to  placebo. Nizatidine  was  
well tolerated. No  patients  dropped  out  of  the  study  but  the  
interpretation  was  limited  by  the  short  study  duration  and  small  sample  
size  
90
. 
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b ) Famotidine :  
Famotidine  is  another  H2  antagonist . A  study  was  done  to  assess  
the effect  of  Famotidine  in  preventing  the  Olanzapine - induced  weight  
gain  in  schizophrenia  patients . Famotidine  was  not  effective  in  
reducing  the  weight  gain . Results  gave  the  inference  that  H2  
antagonists  have  only  limited  utility  in  weight  control 
91
. 
c ) Fluoxetine :   
Fluoxetine  is  an antidepressant  with  selective  serotonin  reuptake  
inhibiting  property . A  study   was  conducted  using  higher  doses  of  
Fluoxetine  ( 60 mg daily ) for  treating  patients  who  gained  more  than  
3%  of  their  weight  with  Olanzapine . The  conclusion  of  the  study  was  
that  the  Fluoxetine  did  not  have  any  weight  reducing  effect 
92
. 
d ) Reboxetine :  
Reboxetine  is  a  selective  norepinephrine  reuptake  inhibitor . 
Weight  gain  with  Reboxetine  was  lesser  in  the  treatment  group . 
Reboxetine  was  well  tolerated . However  the  study  was  weakened  by  
its  short     duration 
93
. 
e ) Amantadine :   
Amantadine  is  an  antiparkinsonian  drug . Amantadine  showed  a  
greater  weight  loss  at  Weeks  8 , 12 , and 16  compared  with  placebo  
when  added  to  individuals  who  had  experienced  weight  gain  of  5%  or  
more with  Olanzapine 
94
 . Amantadine  was  well  tolerated . 
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f ) Sibutramine :  
Sibutramine  has  the  property  of  inhibiting  the  reuptake  of  
serotonin  and  nor epinephrine . Hence  it  is  approved  for  long - term  
treatment  of  obesity. Sibutramine  caused  more  weight  loss  when  
compared  to  placebo  group  in  a  trial . There  was  also  a  mean  (SD)  
increase  in  blood  pressure  of  2.1 (8.5) mm  Hg  and  a  relative  decrease  
of  Hb A1C in  the  sibutramine  group. Sibutramine   reported  no  worsening  
of  psychotic  symptoms 
95
. 
g ) Topiramate : 
Topiramate  is  an  anticonvulsant  medication  that  has  been  used  
also  for  bipolar  affective  disorder  and  for  losing  weight . Topiramate  
200 mg  and  not  Topiramate  100  mg  was  effective  in  inducing  weight  
loss  in  a  study  conducted  in  Korea .The  frequent  side  effect  with  
Topiramate  was  Paresthesia .   Serious  side  effects  such  as  metabolic  
acidosis  were  not  reported . There  was  no  worsening  of  cognitive  
impairment  or  psychotic  symptoms  
96
.   
 h ) Orlistat : 
Orlistat ,  a  lipase  inhibitor  caused  greater  changes  in  waist  
circumference ,  body  mass  index (BMI)  and  insulin  resistance  compared  
to  the controls 
97
. 
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h ) Metformin : 
Only  Metformin  in  the  biguanide  class  of  oral  hypoglycemic  
drugs  is  available  for  use  today 
98
 .                                                                     
 
FIGURE4  
STRUCTURE OF METFORMIN                                                        
 
 
Mechanism  of  action : 
 Metformin  increases  AMPK  activity (AMP - dependent  protein  
kinase)
99
.  
 When  cellular  energy  stores  are  reduced , AMPK  is  activated  by  
phosphorylation . 
 Activated  AMPK  stimulates  glucose  uptake , fatty acid oxidation  
and non oxidative  metabolism .  
 Activated  AMPK  reduces  gluconeogenesis  and   lipogenesis .  
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 The  net  result  of  these  actions  is  lower  rates  of  hepatic  glucose  
production , lower  blood  glucose  levels , increased  glycogen  
storage  in  skeletal muscle and  increased  insulin sensitivity 
10
 . 
Pharmacokinetics : 
Metformin  is  absorbed  primarily  from  the  small  intestine . Its  
transport  into  cells  is  mediated  in  part  by  organic  cation  transporters 
10
. 
Half - life  of  Metformin  is  1.5 – 3  hours. Metformin  is  not  plasma  
protein  bound.  It  is  not  metabolized   and  hence  excreted  unchanged  by  
the  kidneys 
29
 . 
Adverse  effects : 
 The  most  common  adverse  effects  of  Metformin  are  
gastrointestinal  (anorexia, nausea, vomiting, abdominal discomfort, 
and  diarrhea), Which  occur  in  up  to  20 %  of  patients . 
 Lactic  acidosis  is  less  common  with  Metformin 
29
 . 
  Metformin  use  is  associated  with  20 - 30%  lower  blood  levels  of  
vitamin  B12 
100
.  
 
II . Non - pharmacological  interventions : 
The  key  components  for  the  non pharmacologic  management  
obesity  are  diet
81
 , exercise
102
  and  behavioral  therapy
103
 .                             
 
 
59 
 
NOVEL  APPROACHES : 
1 ) Ramipril : 
Ramipril   is  an  ACE  inhibitor . It  has  been  found  to  reduce  the   
cardiovascular  morbidity  and  mortality  by  preserving  endothelial  
function  and slowing  the  progression  of  atherosclerotic  plaque  
formation. It  thereby  reduces  plaque  activation  and  prevents  the  
development of   type  2  diabetes  probably  by  reducing  insulin  
resistance. Hence, Ramipril  may  be  tried  as  a  first  choice  
antihypertensive  agent  in  an  individual  with  hypertension  associated  
with  metabolic  syndrome 
104
 . 
2 ) Acarbose : 
Acarbose  is  an inhibitor of α - glucosidase . Reduction  in  risk  of  
developing  cardiovascular  events  and  reversion  to  normal glucose  
tolerance was  significantly  greater  with  Acarbose 
105
.  
3 ) PPAR-γ agonists : 
Pioglitazone  reduces  multiple  components  of  metabolic syndrome  
such  as  hypertension , high FBS  and  triglycerides . This  drug  also  causes  
decrease  in  urinary  albumin / creatinine  ratio 
106
 . 
4 ) Omega-3 fatty acids : 
In  metabolic  syndrome  patients, 3 gm  of  fish oils (Omega-3  fatty  
acids) have  been  found  to  decrease  ApoB production, decrease 
triglycerides  by  20%  and  marked  reduction  in  small  dense  LDL 
107
. 
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5 ) Surgical  management : 
The  exact  mechanism  of  surgical  procedures  for obesity  remains  
unknown . A  Meta - analysis  involving  136  studies  showed  that   type II  
diabetes  got  improved  in  86.0%  of  patients  who  had  undergone  
bariatric  surgery. In many developed  countries , bariatric  surgery  has  
been  used  for  severe obesity 
108
. Long - term  results  are  not  available . 
Safety  issues  are  in  doubt  due  to  the  recent  reports  of  mortality  and  
morbidity  of  the  procedure  in  the  elderly 
109 
.  
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TREATMENT  ALGORITHM  FOR  THE  MANAGEMENT OF   
METABOLIC  DISTURBANCES  IN  PATIENTS  TREATED  WITH  
ANTIPSYCHOTIC  MEDICATIONS 
110 
 
 
                                      
 
              
                                                                           
                                          
                                                           
 
 
                                      
 
  
  
 
 
 
 
Consideration  of  metabolic risk 
in  choice  of  antipsychotic                 
Patient , family, and  caregiver 
education  about  potential 
metabolic  side - effects 
 
         Lifestyle counselling 
Baseline  screening  and  
regular  monitoring—
more intensively  for first 
3 to 4 months 
 
Referral  to  structured  lifestyle 
intervention 
With  significant  weight gain  
or metabolic disturbance : 
Review  all  medications  from  
both a  metabolic and  a 
psychiatric  perspective 
 
If  unsuccessful , adjunctive 
pharmacotherapy  for  weight 
loss  considered 
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CLINICAL  STUDIES  ON  RISPERIDONE : 
1. A  meta analytical  study  was  conducted  by  Allison  et  al  who  
collected  81  non - english  and  english articles  that  included  the  
data  on  weight  change  in  antipsychotic  treated   patients . The  
results  gave  the  inference  that  among  the  newer  antipsychotic  
agents , mean  increase  in  weight  with  Risperidone  was  2.1  kg
111
 . 
2. In  a  3  month  study  done  on  56,849  patients  with  schizophrenia ,  
Leslie  et  al  concluded  that  the  diabetic  risk  for  Risperidone  was  
the  least  with  the  hazard  ratio  of  1.01  and  the  attributable  risk  
of  diabetes  mellitus  associated  with  Risperidone  was  0.05 %
 112
 . 
3. According  to  a  study  conducted  in  USA  among  147  patients 
taking  Risperidone  for  3  months  with  a  mean  age  of  40.9 , 
Meyer  et  al  suggested  that  the  incidence  of  metabolic  syndrome  
was  30.6%  based  on  ATP - III A  criteria
113
 . 
4. An  Indian  study  done  by  Gautam  et  al  revealed  that  among  90  
patients  given  II  generation  antipsychotics , 10 %  of  patients  
taking  Risperidone developed  metabolic  syndrome  after  4  months  
of  medication
114
 . 
5. With  the  mean  dose  of  3.6 mg/day  of  Risperidone  for  12  weeks  
in  first  episode  psychosis  patients , Iglesias  et  al  found  that  the  
significant  weight  gain  with  Risperidone  was  5.6  kg ( S.D = 4.5).  
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However  there  were  no  significant  changes  in  glucose  
metabolism  after  12  weeks
115
 . 
CLINICAL  STUDIES  ON  METFORMIN: 
1. In  a  historical  cohort  study  by  Mourao  Junior  et  al  involving  57  
type 2 diabetes  patients  with  metabolic  syndrome  and  on  insulin  
who  were  assessed  by  a  paired  analysis  before  and  after  the  
addition  of  Metformin , it  was  found  that  there  was  significant  
reduction (p<0.05)  of  BMI (30.7 ± 5.4  to  29.0 ± 4 kg/m
2
 ) and  WC 
( 124.6 ± 11.7 to 117.3 ± 9.3 cm) with  Metformin
116
 . 
2. Yanovski  et  al  conducted  a  randomized , double  blind , placebo  
controlled  trial  consisting  of  100  severely  obese , insulin  resistant  
children  aged  6 - 12  years  randomized  to  1000 mg  Metformin (or) 
placebo  for  6  months  followed  by  a  open - labelled  Metformin  
treatment  for  6  months  and  concluded  that  Metformin  had  
significantly  caused  greater  decrease  in  BMI (difference , -1.09 
kg/m
2
, p=0.006 ) . Fasting  glucose  (p=0.007) improved  more  in  
Metformin  treated  children  than  in  placebo  treated  children
117
 . 
3. Wulffele  et  al  reviewed  41  studies  that  included  that  included  
randomized  controlled  trial  in  patients  with  type II  diabetes  
mellitus  and  Metformin  treatment  lasting  for  atleast  6  weeks  and  
demonstrated  that  there  was  significant  reduction  in  plasma  
triglycerides [diff  (-0.26)  (-0.34 to -0.18) mmolL
-1
 , p<0.0001] 
118
.  
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4. Double - blind , placebo  controlled  study  involving  29  adolescents  
was  conducted  by  Freemark  et  al  and  it  revealed  that  Metformin  
caused  a  progressive  decline  in  FBS (from  a  mean  of  84.9  to  
75.1 mg% )  and  a  decline  of  0.12  standard  deviation  in  study  
participants (-1.3%  from  baseline)
119
 . 
CLINICAL  STUDIES  ON  METFORMIN  ALONG  WITH  
ATYPICAL  ANTIPSYCHOTICS: 
1. Wu  et  al  conducted  a randomized  control  trial  involving  40  first  
episode  psychosis  patients  to  determine  the  impact  of  Metformin  
in  patients  newly  commenced  on  Olanzapine . Patients  had  a  
mean  age  of  25  years  and  normal  BMI  at  study  beginning . 
Weight , BMI , waist to hip  ratio  levels ,WC  increased  less  in  the  
Olanzapine + Metformin  group  relative  to  Olanzapine + Placebo  
group  during  12 week  follow up  period
8
 . 
2. Study  conducted  by  Baptista  et  al  in  40  patients  with  
schizophrenia  with  a  mean  age  of  47.7  years , investigated  the  
efficacy  of  Metformin  in  patients  newly  commenced  on  
Olanzapine . This  is  the  only  study  investigating  Metformin  for  
prevention  of  weight  gain  in  chronic  patients  newly  commenced  
on  II  generation  antipsychotic  medications . This  RCT  showed  
reduction  in  blood  sugar  levels  and  triglycerides  independent  of  
weight  loss  in  the  Metformin  group
120
 . 
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With  the  above  extensive  literature  review , due  to  the  feasibility  
of  Risperidone  and  Metformin  in  our  hospital  setting  and  due  to  the  
paucity  of  trials  using  both  these  drugs , we  conducted  this  study  using   
Metformin  and  Risperidone  to  evaluate  the  effectiveness and  safety  of  
Metformin  along  with  Risperidone  to  prevent  antipsychotic - induced  
metabolic  syndrome  in  first episode  schizophrenia  patients. 
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AIM OF THE STUDY 
To  evaluate  the  effectiveness and  safety  of  Metformin  along  with  
Risperidone  to  prevent  antipsychotic - induced  metabolic  syndrome  in  
first episode  schizophrenia  patients. 
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METHODOLOGY 
STUDY  DESIGN : 
Open - labelled, randomized, prospective, comparative, single  
centered,  parallel  group  study . 
STUDY  DURATION : 
March  2013 - February 2014 . 
STUDY  CENTRE : 
Department  of  Psychiatry , Tirunelveli  Medical  College  Hospital , 
Tirunelveli . 
SAMPLE  SIZE : 
Total  of  96  patients ( 48  each  in  group ). 
INCLUSION CRITERIA: 
 Patients  with  18  to  40  years  of  age  who  have  been  diagnosed  
with first  episode  schizophrenia  based  on  DSM - IV criteria  and  
on  treatment  with    T . Risperidone  2 mg twice  a  day  for  ≤  2  
months . 
EXCLUSION CRITERIA: 
 Uncooperative , aggressive  patients . 
 Patients  with  suicidal  tendency . 
 Pregnant  and  lactating  women. 
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 Patients  with   history  of  liver  disease/ renal  disease/ cardiovascular  
disease/ diabetes  mellitus/ hypertension/  dyslipidemia/ substance  
abuse / seizure  disorder / malignancy . 
 Patients  with  diagnosis  other  than  schizophrenia . 
 Patients  with  mental  retardation . 
 Patients  who  are  taking  other  drugs  that  may  affect  body  weight  
(Carbamazepine, Lithium, Topiramate, antidepressants, Valproate and 
hormone  replacement  therapy)  
 Patient  who  is  on  special  diet  or  who  do  exercise  for  weight 
loss. 
ETHICAL  CONSIDERATIONS : 
The  study  was  commenced  after  getting  approval  from  the  
Institutional  Ethical  Committee . Written  informed  consent  was  obtained  
in  local  vernacular  language  from  every  patient  (or) his  reliable  
caregiver before  enrollment . 
SCREENING : 
Based  on  the  inclusion and  exclusion  criteria, the  subjects  were  
enrolled  in  the  study  after  initial  screening . Initial  screening  at  baseline  
included  clinical  assessment, anthropometric  measurements  like  weight, 
height  and  waist  circumference and  laboratory  investigations  like  
complete  blood  count, fasting  blood  sugar, serum  urea , serum  creatinine,  
liver  function  tests , routine  urine  analysis and  fasting  lipid  profile . 
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RANDOMISATION  AND  ENROLLMENT : 
Subjects  who  were  initiated  on  T . Risperidone  2 mg  orally  twice  
daily  for  ≤ 2  months   for  first  episode  schizophrenia  were  randomized  
using  computer  generated  table  into  two  groups . 
GROUP 1 : Patients  were  given  T. Risperidone  2 mg   alone , orally , 
twice  daily  after  food .  
GROUP  2 : Patients  were  given   T.Metformin  500 mg  orally , twice  
daily  after  food  along  with  T.Risperidone . 
T.Risperidone  and  T.Metformin  remained  at  a  fixed  dose  as  
baseline  levels  throughout  the  course  of  treatment . All  subjects  were  
under  the  care  of  another  adult  caregiver (or) their  parents  who  
monitored  and  recorded  drug  intake  everyday  to  confirm  adherence . 
CONCOMITANT  MEDICATIONS : 
Only  T. Trihexyphenidyl (5 - 10 mg/day)  for  extrapyramidal  
symptoms  (or)  T.Lorazepam (1-3 mg/day)  for  insomnia (or)  agitation  
were  given  when  needed . 
COMPLIANCE : 
The  compliance  in  both  the  group  of  patients  were  assessed  
using  pill count . Patients  were  asked  to  return  the  empty  strips  when  
they  come  for  receiving  the  drugs . 
 
 
70 
 
EFFICACY  PARAMETERS : 
PRIMARY  ENDPOINT : 
A. Proportion  of  patients  developing  metabolic  syndrome  at  the  end  
of   6  months  in  both  the  groups . 
SECONDARY  ENDPOINTS : 
B. Changes  in  body  mass  index  from  baseline  to  the  end point               
(after  6  months  of  treatment) . 
C. Proportion  of  patients  progressing  a  stage  higher  from  the                    
baseline   in  terms  of  BMI  at  the  end  of  3  months . 
D. Changes  in  waist  circumference  from  baseline  to  the  end point . 
E. Changes  in  fasting  blood  sugar  from  baseline  to  the  endpoint . 
F. Changes  in  fasting  triglycerides  from  baseline  to  the  endpoint . 
All  the  above  parameters  were  assessed  in  fasting  state . Fasting  as 
confirmed  with  patients  (or) caregivers  at  the  time  of  assessment. 
Parameter  assessment : 
A) Body  Mass  Index (BMI)  measurement : 
Height : 
            All  subjects  were  instructed  to  remove  their  shoes  and  socks  
before  the  procedure . Subjects  were  instructed  to  stand  on  a  level  
floor  with  the  feet  parallel  and  pointing  forwards . Subjects  were  asked  
to  stand  unsupported  by  not  touching  the  nearby  wall  (or) furniture .  
Subjects  were  asked  to  stand  as  tall  as  possible  such  that  the  the 
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lower  border  of  the  left  orbit  and  the  upper  margin  of  the  external 
auditory  meatus   remain  horizontal. Subjects  were  instructed  to  breathe  
out  gently  during  the  measurement. The measure  was  placed  on  the 
subjects  head   to  ensure  that  the  spirit  level  is  balanced. The  measured  
height  was  expressed  in  centimeters. 
Weight : 
The  subjects  were  instructed  to  remove  the  shoes, excess  clothing  
and  overcoats . Pockets  containing  keys  and  wallet  was  emptied . Any  
heavy  jewellery  worn  by  the  subject  was  removed. Weight  was  
measured  using  a  manual  weighing  scale . The weighing scale  platform  
was  placed  on  an  even  floor  surface . Before  the  subject  stepped  onto  
the  platform , it  was  ensured  that  the viewfinder  displayed  [0.0]  before  
the  measurement. The subjects  were  instructed  to  stand  still  on  the  
scales  platform. Subjects   were  asked  to  stand  free  without  leaning  on  
a  chair  (or) wall.  Subjects  were  instructed  to  exhale  gently  during  the  
measurement.  The  weight  was  measured  in  kilograms . Once  the weight  
was  recorded , the  subjects  were  instructed  to  stand  off  the  platform  
and re-apply  their  over clothes and  shoes . 
BMI  calculation : 
BMI (or) Quetelet  index  was  calculated  using  the  formula              
[ weight(kg) / (height (m) )
2
 ] . BMI  was  graded  as  follows . 
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        Underweight - < 18.5 
                             Normal - 18.5 to 25 
                             Overweight - 25 to 30 
                             Obese - > 30 .    
Also  the  proportion  of  subjects  progressing  from  a  stage  at  
baseline  to  the  next  higher  stage  at  3  months  were  noted  in  both  the  
groups  and  entered  in  a  2 × 2  table .               
B ) Waist  circumference : 
The  subjects  were  instructed  about  the  procedure  and  permission  
acquired  to  remove  the  clothing  as  it  may  restrict  the  accurate  
measurement. A  flexible  measuring  tape  was  used  to  measure  the  waist  
circumference  in  standing  position. It  was  ensured  that the  tape  was  
neither  tight  nor  loose  such  that  it  fits  snugly. Subjects  were  instructed  
to  breathe  out  normally  during  the  measurement  and  the  waist  
circumference  was  measured  at  a  point  midway  between  the  lowest  rib  
and  greater  trochanter  with  the  subject's  hands  placed  loosely  by  the  
side. Waist  circumference  was  rounded  off  to  nearby  whole  number  
and  expressed  in  centimeters . 
C) Blood  investigations : 
Patients  were  previously  instructed  to  come  for  follow  up  visits  
with  10  hrs  of  fasting. The  subjects  were  made  to  sit  comfortably  in  a  
chair  and  informed  about  the  procedure. After  sterilizing  our  hands  
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upto  the  elbows , a  tourniquet  was  placed  3  to 4  inches  above  the  
selected  puncture  site  neither  tight  nor  too  loose  in  the  subjects  not  
longer  than  1 minute. Then  after  wearing  the  non - latex  glove , the  vein  
was  palpated  and  the  area  above  it  was  cleansed  and  air dried. The  
subject  was  asked  to  make  a  fist  and  the  arm  was  firmly  grasped  to  
make  the  skin  taut  and  vein  anchored  such  that  at  an  angle  of  15 - 30  
degrees  with  the  arm  surface , needle  was  inserted  and  2 ml  of  blood  
was  withdrawn.  Blood  was  collected  in  a  sterilized, dry  container   for  
further  investigation . 
 Fasting  blood  sugar : 
        Using  the  sample  as  obtained  above, fasting  blood  sugar  levels  
were  assessed  using  the  auto analyzer. 
 Fasting  Triglycerides : 
       Using  the  sample  as  obtained  above, fasting  triglyceride  levels  
were  assessed  using  the  auto analyzer. 
FOLLOW UP  VISITS : 
Follow up  was  done  at  the  end  of  3rd and  6th  months  of  
starting  the  treatment . Patients  were  reminded  of  their  follow up  visits  
by  a  telephone  call  on  the  previous  day . During  the  follow up , 
anthropometric  measurements  such  as  weight, height and waist  
circumference  were  recorded  and  fasting  blood  samples  were  taken  to  
assess  the  blood  sugar  and  triglycerides . Patients  were  given  a  diary  
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after  enrollment   to  record  the  adverse  effects  and  the  diary  was  
checked  at  every  follow up  visit . Patients  were  also  enquired  about  the  
use  of  concomitant  medications  through  3  and  6  months . 
STATISTICAL  ANALYSIS : 
Statistical  analysis  was  performed  with  the  help  of  statistical  
package  SPSS (Statistical  Package  for  the  Social  Sciences)  version  11 .  
1. Baseline  characteristics  of  both  the  groups  were  tabulated  by  
descriptive  statistics (mean , standard  deviation)  and  frequency  
table. They  were  matched  by  unpaired  student 't' test  and  
Pearson's  chi - square  test . 
2. Between  group  analysis  was  done  using  unpaired  student  't' test  
at  baseline , 3 months  and  6  months.  
3. The  student  paired  't'  test  was  applied  for  analysis  and  
interpretation  within  the  group  at  varied  intervals  as  mentioned  
above.  
4. The  categorical  variables (BMI  staging  and  development  of  
metabolic  syndrome)  between  two  groups  were  compared  by  Chi 
- square  test . 
5. Adverse  events  were  expressed  in  percentage . 
The  p  values  less  than  0.05 (p<0.05)  was  considered  as  significant  
in  two  tailed  condition . 
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PATIENT  DISPOSITION : CONSORT  DIAGRAM : 
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RESULTS  
                     For  a  period  of  one  year  from  March  2013  to  February  
2014, around  112  patients  newly  diagnosed  with  schizophrenia  were  
initially  screened .  Based  on  the  inclusion  and  exclusion  criteria , around  
96  patients  were  enrolled  for  the  study. They  were  randomly  assigned  
through  computer  generated  table  into  2  groups  receiving  either  
Risperidone  alone (or) Metformin  along  with  Risperidone . All  the  patients  
completed  the  study  and  the  results  were  analyzed . 
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TABLE - 5 
                               
                                  BASELINE CHARACTERISTICS  
 
Baseline 
parameters 
Group 1 
(n=48) 
Group 2 
(n=48) 
'p'  value 
Age 
(Mean ± SD) yrs 
 
29.69 ± 5.78 
 
28.75 ± 4.56 
 
0.88
 
Gender 
n (%) 
Male 26 (54) 28 (46) 
0.68
 
 
Female 
 
22 (46) 
 
20 (54) 
BMI 
(Mean  
±SD)(kg/cm
2) 
 
22.61 ± 4.03 
 
26.29 ± 4.57 
<  0.001
 
WC 
(Mean ± SD) cms 
84.48 ± 12.17 89.69 ± 13.25 0.04
 
FBS 
(Mean ± SD) mg% 
90.46 ± 23.47 99.52 ± 30.54 0.1
 
TGL 
(Mean ± SD) mg% 
146.42 ± 
66.26 
164.10 ± 81.64 0.25 
 
Table  5 shows  the  baseline  characteristics  in  both  the  groups . Baseline    
characteristics  were  similar  in  both  the  groups ( p>0.05)  except  that  the   
patients  in  group II  had  higher  BMI  levels (p < 0.001)  and  larger  waist   
circumference  levels (p = 0.04) . 
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TABLE 6 
PROPORTION OF  PATIENTS  DEVELOPING  METABOLIC  
SYNDROME  AT  THE  END  OF  6  MONTHS  IN  BOTH  THE  GROUPS 
Groups Yes No 'p' value 
Group I 10 38 
0.01
* 
Group II 1 47 
\ 
 * p value < 0.05 - statistically  significant 
According  to  the  WHO  criteria  for  metabolic  syndrome , it  was  
found  that  10  patients  in  group I  developed  metabolic  syndrome  and  1  
patient  in  group  II  developed  metabolic  syndrome . The  Pearson  Chi  
Square  test  was  used  to  test  the  association  between  the  two groups  
and  the  p value  was  found  to  be  < 0.05  implying  significant  difference  
between  the  groups . 
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TABLE  7 
CHANGE  IN  WAIST  CIRCUMFERENCE IN  GROUP II PATIENTS 
(RISPERIDONE +METFORMIN)  WITH  RESPECT  TO  BASELINE 
Time Mean C.I 'p' value 
Baseline 89.7 - - 
End  of  3 
months 
 
89 ( -0.9 to -0.4) < 0.001
* 
End  of  6 
months 
 
87.8 ( -2.3 to -1.6) < 0.001
* 
 
* p  value < 0.05 - statistically  significant . 
There  was  a  significant  reduction  in  waist  circumference  at  the  
end  of  3  months  (p < 0.001)  and  at  the  end  of  6  months (p < 0.001)  
when  compared  to  baseline  in  group II  individuals . 
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TABLE 8 
COMPARISON  OF  CHANGE  IN  WAIST  CIRCUMFERENCE  FROM 
BASELINE  BETWEEN  GROUP I  AND GROUP II . 
 
Visits Groups 
Mean 
Difference 
From 
Baseline 
C.I 'p' value 
End  of  3 
months 
Group I 2.50 
( 2.4 to 4) 
 
< 0.001
* 
Group II -0.67 
End  of  6 
months 
 
Group I 3.75 
( 5 to 6.4) 
 
< 0.001
* 
Group II -1.94 
 
* p value < 0.05 - statistically  significant . 
Table  8  shows  statistical  difference in  waist  circumference  levels  
between  both  the  groups  at  the  end  of  3  months (p < 0.001)  and  at  
the  end  of  6  months (p < 0.001)  . 
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FIG 5 
CHANGES  IN  WAIST  CIRCUMFERENCE  IN  BOTH  THE 
GROUPS  AT  THE  END  OF  3  AND  6  MONTHS . 
 
 
81
82
83
84
85
86
87
88
89
90
G
ro
u
p
 1
G
ro
u
p
 2
G
ro
u
p
 1
G
ro
u
p
 2
G
ro
u
p
 1
G
ro
u
p
 2
Baseline 3 months 6 months
84.5
89.7
87
89
88.2 87.8
W
C
  
in
  
c
m
s
Time
WAIST CIRCUMFERENCE
Baseline Group 1
Baseline Group 2
3 months Group 1
3 months Group 2
6 months Group 1
6 months Group 2
 
 
 
                                                               
                                                                        
82 
 
TABLE 9 
CHANGE  IN BODY MASS INDEX IN  GROUP II PATIENTS  WITH 
RESPECT  TO BASELINE . 
 
         
      Time 
       
      Mean 
         
         C . I 
    
     'p'  value 
 
       Baseline 
 
         26.3 
 
          - 
 
            -      
   
     
    End  of  3    
 
      Months 
         
        25.5 
     
     (-0.9 to -0.6) 
    
     < 0.001
* 
   
    End  of  6    
 
      months  
         
        24.8 
     
     (-1.8 to -1.3) 
     
     < 0.001
* 
* p value < 0.05 - statistically  significant . 
There  was  a  significant  reduction  in  BMI  at  the  end  of  3  
months  when  compared  to  baseline (p <0.001)  in  group II  individuals. 
Also  the  BMI  reduction  at  the  end  of  6  months  with  respect  to  
baseline  was  also  statistically  significant (p < 0.001) .  
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TABLE 10 
COMPARISON  OF  CHANGE  IN  BMI  FROM  BASELINE  
BETWEEN  GROUP I  AND  GROUP II . 
 
Visits Groups 
Mean 
Difference 
From  
baseline 
C.I 'p'  value 
End  of  
3 
months 
 
Group 1 0.99 
(1.4 to 2) 
 
< 0.001
* 
Group 2 -0.71 
End  of 
6  
months 
 
 
Group 1 1.93 
(3.1 to 3.9) < 0.001
* 
Group 2 -1.53 
 
* p  value < 0.05 - statistically  significant . 
There  was  a  significant  statistical  difference  between  both  the  
groups  at  the  end  of  3  months (p <0.001) and  at  the  end  of  6  months 
(p < 0.001)  in  BMI . 
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FIG 6 : 
CHANGES  IN  BMI  IN  BOTH  THE  GROUPS  AT  THE  END  OF  3 
AND  6  MONTHS . 
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TABLE  11 
PROPORTION  OF  PATIENTS  PROGRESSED  TO  A  STAGE  HIGHER  
FROM  THE  BASELINE  IN  TERMS  OF  BMI  AT  THE  END  OF  3  
MONTHS . 
Proportions of  patients 
'p' value 
Groups Yes No 
Group 1 8 40 
0.003
* 
Group 2 Nil 48 
 
* p  value < 0.05 , statistically  significant . 
Table 11  shows  the  proportion  of  patients  who  progressed  a  
stage  higher  from  baseline  in  terms  of  BMI , 3  months  after  treatment . 
When  compared  to  group  I , significantly  lesser  proportion  of  patients  
in  group  II  progressed  to  the  next  stage . The  Pearson  Chi  Square  test  
was  used  to  test  the  association  between  the  two groups  and  the  p 
value  was  found  to  be  < 0.05  implying  significant  difference  between  
the  groups .   
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TABLE  12 
CHANGE  IN FASTING  BLOOD  SUGAR  LEVELS  IN  GROUP II 
PATIENTS  WITH  RESPECT  TO  BASELINE 
 
 
* p  value < 0.05 - statistically  significant . 
Table 12  demonstrates  a  significant  reduction  in  FBS  levels  at  
the  end  of  6  months  of  treatment (p < 0.001)   in  group  II  individuals .   
 
  
Time Mean C.I 'p' value 
Baseline 99.5 - 
 
- 
End  of  3 
months 
 
102 ( -2 to 7.1) 0.28 
End  of  6 
Months 
94 ( -10 to -1.3) < 0.001
* 
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TABLE  13 
COMPARISON  OF  CHANGE  IN  FASTING  BLOOD  SUGAR  LEVELS  
FROM  BASELINE  BETWEEN  GROUP I  AND  GROUP II . 
 
Visits Groups 
Mean 
Difference 
From 
baseline 
C.I 'p' value 
End  of 
3   months 
Group 1 15.81 
(6.3 to 20.3) 
 
< 0.001
* 
Group 2 2.52 
End of 
6  months 
Group 1 28.04 
 
(26.3 to 41) 
< 0.001
* 
Group 2 -5.58 
 
* p  value < 0.05 - statistically  significant . 
Table  13  shows  statistical  difference  in  FBS  levels  between  both  
the  groups  at  the  end  of  3 months (p < 0.001)   and  at  the  end  of  6  
months  of  treatment (p < 0.001)  . 
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FIG  7 
 
CHANGES  IN  FBS  LEVELS  IN  BOTH  THE  GROUPS  AT  THE  
END  OF  3  AND  6  MONTHS 
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TABLE  14 
 
CHANGE  IN  FASTING  TRIGLYCERIDE  LEVELS  IN  GROUP II 
PATIENTS  WITH  RESPECT  TO  BASELINE 
 
Time Mean C.I 'p' value 
Baseline 164.1 - - 
End  of  3 
Months 
161.5 ( -10 to 4.8) 0.49 
End  of  6 
Months 
150.3 ( -19.8 to -7.7) < 0.001
* 
* p value < 0.05 - statistically significant . 
Table 14  demonstrates  no  significant  changes  in  TGL  levels  at  
the  end  of  3  months (p = 0.49)  with  respect  to  baseline  in  Metformin  
group . However  there  was  a  significant  reduction  in  TGL  levels  at  the  
end  of  6  months (p < 0.001)  in  group  II  individuals .   
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TABLE  15 
COMPARISON  OF  CHANGE  IN  FASTING  TRIGLYCERIDE  
LEVELS  FROM  BASELINE  BETWEEN  GROUP I  AND GROUP II 
 
Visits Groups 
Mean 
Difference 
From 
Baseline 
C.I 'p' value 
End  of  3 
Months 
Group 1 36.83 
(22 to 57.1) < 0.001
* 
Group 2 -2.58 
End  of  6 
months 
Group 1 45.21 
(43 to 75.1) < 0.001
* 
Group 2 -13.77 
 
* p value < 0.05 - statistically  significant . 
Table  15  shows  significant  rise  in  TGL  levels  at  the  end  of  6  
months  compared  to  baseline  in  group I  individuals  and  similarly  
Metformin  along  with  Risperidone  has  significantly  caused  reduction  in  
TGL  levels  at  the  end  of  6  months  in  group II  individuals  signifying  
the  existence  of  statistical  difference  between  both  the  groups . 
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FIG 8 
CHANGES  IN  TGL LEVELS  IN  BOTH  THE  GROUPS  AT  THE  
END  OF  3  AND  6  MONTHS 
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Adverse  effects : 
       Metformin  was  tolerated  well  by  the  study  participants .The  
treatment  emergent  adverse  effects  with  Metformin  were  mainly  
gastrointestinal  side  effects  such  as  diarrhea  and  gastritis . They  were  
reported  by  5%  of  patients  and  were  transient . It  did  not  lead  to  the  
discontinuation  of  the  drug . There  were  no reports  suggestive  of  lactic  
acidosis  (or)  hypoglycemia .  
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Discussion : 
Schizophrenia  is  considered  the  prototypic  disorder  for  
understanding  the  phenomenology  of  psychosis 
3
 . It  is  associated  with  
a  high  morbidity  and  mortality  resulting  from  strikingly  high  suicide  
rate  of  10 %
4
. Atypical  antipsychotics  are  commonly  used  for  managing  
schizophrenia  spectrum  disorders  nowadays . However  their  benefit - to - 
risk  ratio  is  challenged  by  metabolic  abnormalities  and  weight gain
82
 . 
Individuals  suffering  from  both  psychotic  illness  and  obesity  encounter  
the  dual  stigma  and  discrimination  that   contributes  to  poor  self  esteem  
and  psychological  distress  and  may  impact  medication  compliance  
thereby  leading  to   relapse
121
 . 
Adherence  to  medications  is  difficult  and  also  physical  
interventions  may  not  be  possible  in  psychiatric  patients . Net  weight  
loss  in  chronic  patients  who  have  undergone  indeterminate  weight  gain  
seems  to  be  more  difficult . But  weight  gain  mitigation  at  early  stages  
of  treatment  seems  to  be   more  easier  and  clinically  advantageous . 
Adverse  cardio metabolic  effects  of  atypical  antipsychotics  may  be  
minimized  by  several  strategies  such  as  a) healthy  lifestyle  
intervention
122
,  b) switching  to  lower risk  antipsychotics
123
  and  c) the  
addition  of  medication  that  may  reduce  body  weight  and / (or)  lipid  
and  glucose  parameters
124
.  
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Metformin  has  a  well  established  safety  profile  in  both  
adolescents  and  young  adults  in  contrast  to  the  other  weight  reducing  
drugs  which  have  potential  serious  adverse  effects. Importantly  
Metformin  is  not  metabolised  by  hepatic  P450  enzymes. Hence  
significant  drug - drug  interactions  are  not  reported. Also  there  exists  no  
specific  interactions  with  antipsychotic  medication
125
. Hence  the  present  
study  was  aimed  to  evaluate  the  effectiveness  and  safety  of  Metformin  
along  with  Risperidone  in  preventing  the  occurence of   antipsychotic - 
induced  Metabolic  syndrome   in  first  episode  schizophrenia  patients .   
As  the  prevalence  of  metabolic  syndrome  per  se  is  common  
after  40  years , we  conducted  the  study  only  in  adolescents  and  young  
adults (18 to 40 years). The  mean  age  in  group I (Risperidone alone)  was  
(29.69 ± 5.78) years  and  that  in  group II (Metformin + Risperidone)  was  
(28.75 ± 4.56) years. In  our  study , baseline  characteristics  were  similar  
in  both  the  groups (p > 0.05)  except  that  the  patients  in  group II  had  
higher  BMI  levels (p < 0.001)  and  larger  waist  circumference  levels (p = 
0.04) . 
With  regard  to  the  primary  endpoint, the  development  of   
metabolic  syndrome  was  assessed  in  both  the  group  of  patients  using  
the  WHO  criteria  for  metabolic  syndrome . 10  patients (21%)  in  group I   
and  1  patient (2%)  in  group  II  developed  metabolic  syndrome  thereby  
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implying  that  Metformin  seems  to  be  effective  in  reducing  the  
incidence  of  metabolic  syndrome .  
The  secondary  endpoints  in  our  study  were  the  individual  
components  of  metabolic  syndrome (Changes  in  WC , BMI , FBS and 
TGL). Waist  circumference  has  better  correlation  with  abdominal  fat  
and  is  strongly  associated  with  cardiovascular  risk  factors  when  
compared  to  other  parameters
126
 . Increase  in  waist  circumference  of  
every  2  inches  is  associated  with  an  increase  in  mortality  by  17%  in  
men  and  13%  increase  in  women .  
Recent  studies  suggest  that  the  ability  of  subcutaneous  fat  depots  
to  store  excess  energy  is  limited . This  results  in  an  "overflow"  of  
excess  energy  to  'ectopic  sites'  such  as   skeletal  muscle and  liver  and   
intra abdominal  adipose  tissue . This  excessive  ectopic  fat  eventually  
leads  to  metabolic  dysfunction  in  organs  and  so  increase  in   intra 
myocellular  fat  is  found  to  be  associated  with  skeletal  muscle  insulin  
resistance
127
  and  increase  in  intrahepatic  fat  is  associated  with  hepatic  
insulin  resistance
128. 
Metformin  suppresses  appetite  and  causes  satiety  through  an  
increase  in  insulin  sensitivity  and  reduction  in  hyperinsulinemia . GLP - 
1 (incretin) released  from  L  cells  in  intestine  via  glucose  dependent  
insulin  secretion  lowers  blood  glucose  levels  and  promotes  satiety  by  
slowing  gastric  emptying . In  a  study  by  Mannuci  et  al , it  was  found  
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that  the  reduced  intake  of  food  and  weight  loss  in  Metformin  treated  
subjects  might  be  related  to  the  increase  in  GLP-1  levels
129
 .    
In  our  study , within  the  group , group  II  showed  mean  waist  
reduction  of  (-1.9 cms)  from  the  baseline  at  the  end  of  6  months . This  
implies  that  waist  circumference  reduction  by  Metformin  will  have  
positive  impact  in  preventing  metabolic  syndrome . 
Waist  circumference  is  a  marker  of  central  obesity ,  whereas  
BMI  is  a  measure  of  overall  adiposity
126
 . BMI  is  strongly  associated  
with  cardiovascular  mortality  which  is  partially  due  to  the  effect  of  
obesity  on  lipoprotein  metabolism , blood  pressure  and insulin  
resistance
130
 . However  cardiovascular  disease  is  better  predicted  with  
BMI  coupled  together  with  WC  than  with  the  BMI  alone
131
 . In  our  
study , mean  baseline  BMI  value  got  reduced  from  26.29  to  25.5  at  3  
months  and  24.8  at  6  months  of  treatment. These  results  were  similar  
to  the  study  done  in  USA  by  Morrison  et  al  which  demonstrated  
significant  (2.22 kg/m
2
)  reduction  in  BMI  with  Metformin  in  children  
taking  Risperidone , Olanzapine , Quetiapine  (or) Valproate
132
 . Hence  
both  BMI  and  WC  play  a  crucial  role  in  the  assessment  of  metabolic  
syndrome
126
 and  metformin  along  with  Risperidone  has  been  found  to  
decrease  both  waist  circumference  and  BMI   suggesting  its  importance  
in  the  prevention  of  metabolic  syndrome .  
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As  we  all  know  about  the  microvascular  and  macrovascular  
complications  associated  with  long term  hyperglycemia , normalization  of  
fasting  blood  sugar  levels  at  the  earliest  is  considered  wise  in  the  
prevention  of  metabolic  syndrome . Metformin  reduces  fasting  blood  
sugar  levels  by  increasing  the  peripheral  utilisation  of  glucose
10
 . In  our  
study , fasting  blood  sugar  levels  did  not  show  any  statistical  difference  
at  3  months  of  treatment (p=0.28)  which  was  comparable  to  the  results  
of  the  study  by  Carrizo  et  al  that  interpreted  that  Metformin  had  no  
significant  effect  on  fasting  BSL  compared  with  placebo  at  14  weeks  
of  treatment
133
 . But  in  our  study  at  6  months  of  treatment , there  was  
a  significant  reduction  in  fasting  BSL (p <0.001) . This  result  was  
similar  to  the  double - blind ,  placebo  controlled  study  conducted  by  
Baptista  et  al  showing  significant  fasting  BSL  reduction  after  
Metformin  addition (p=0.02)
120
 . 
Elevated  triglycerides  along  with  increased  waist  cicrumference  is  
termed  as  hypertriglyceridemic  waist  which  is  found  to  have  
association  with  arteriographic  CVD
134
 . Also  TG  elevation  is  found  
associated  with  stroke  and  MI  risk  in  NHANES III
135
 . Metformin  
increases  AMPK  and  hormone  sensitive  lipase  activities  in  brown  
adipose  tissue  thereby  lowering  TGL  by  enhancing  uptake  of  VLDL - 
TGL , lipolysis  of  intracellular  TGL  and  subsequent  fatty  acid  oxidation  
by  mitochondria
136
 .  
98 
 
In  our  study , fasting  triglyceride  levels  did  not  differ  statistically  
at  3  months  when  compared  to  baseline (p=0.49)  in  group II  
individuals . However  the  mean  triglyceride  level (164.1 mg%)  at  
baseline  dropped  down  (150.3 mg%)  at  6  months  suggesting  there  was  
significant  statistical  difference  at  6  months (p<0.001) . This  result  was  
similar  to  the  study  conducted  by  Shin  et  al  which  showed  significant  
reduction  in  triglyceride  levels  after  12  weeks  of  treatment  with  
Metformin
137 . 
     
Thus  our  study  has  shown  that  Metformin  is   effective  and  safe  
in  preventing  the  occurence  of  antipsychotic  induced  metabolic  
syndrome  in  adolescents  and  young  adults  with  first  episode  
schizophrenia.  
Our  study  has  some  limitations . First , as  the  duration  of  study  is  
only  6  months , we  do  not  know  whether  the  improved  BMI, WC, FBG  
and  TGL  levels  could  be  sustained . 
Second , all  our  study  participants  were  cared  by  their  caregivers  
(or) parents and  hence  they  could  have  better  adherence  with  Metformin  
when  compared  to  patients  living  independently  with  schizophrenia . 
Hence  due  to  the  feasibility  of  Risperidone  and  Metformin  in  
our  hospital  setting  and  due  to  the  paucity  of  trials  using  both  these  
drugs , we  conducted  this  study  using  Metformin  and  Risperidone . 
Further  studies  with  more  number  of  patients , long  term  follow  up  
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and  Metformin  along  with  lifestyle  intervention  would  provide  more  
appealing  results  regarding  the  efficacy  and  safety  of  Metformin    for  
the  prevention  of  antipsychotic  induced  metabolic  syndrome . 
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                                                       CONCLUSION  
 To  conclude, the  use  of  Metformin  along  with  Risperidone  is  
safe  and  effective  in  the  prevention  of  metabolic  syndrome  
induced  by  atypical  antipsychotics . 
 This  may  have  a  good  impact  on  the  long  term  cardiovascular  
morbidity  and  mortality  of  the  schizophrenia  patients .                                     
 
APPENDIX (i) 
ABBREVIATIONS 
AACE                   :American Association of Clinical Endocrinology 
ACEI                     :Angiotensin Converting Enzyme Inhibitor 
AHA                      :American Heart Association 
AMPK                   :AMP dependent Protein Kinase 
BMI                       :Body Mass Index 
BSL                       :Blood Sugar Level 
CATIE study         :Clinical Antipsychotic Trials of Intervention Effectiveness   
                                study  
CTZ                       :Chemoreceptor Trigger Zone 
CUtLASS              :Cost Utility of Latest Antipsychotic drugs in  schizophrenia   
                                Study 
DALY                   : Disability Adjusted Life Years 
DLPFC                  : Dorsolateral Prefrontal Cortex 
DSM                      : Diagnostic and Statistical Manual of Mental disorders 
ECT                       : Electro Convulsive Therapy 
EGIR                     : European Group for the study of Insulin Resistance 
EPS                        : Extrapyramidal side effects 
FBS                       : Fasting Blood Sugar 
HAART                 : Highly Active Anti Retroviral Therapy 
ICD                        : International Classification of Diseases 
IDF                        : International Diabetes Federation 
LAI                        : Long acting Injectables 
MetS                      : Metabolic syndrome 
NCEP:ATPIII       : National Cholesterol Education Program : Adult Treatment  
                                Panel III 
NHANES III         : National Health And Nutrition Examination Survey III 
NHLBI                  : National Heart,Lung and Blood Institute 
NIMH                    : National Institute of Mental Health 
RDC                      : Research Diagnostic criteria 
TGL                      : Triglycerides 
VMPFC                : Ventromedial Prefrontal Cortex 
WC                       : Waist Circumference 
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jLf;Fk; nghUl;L nkl;ghh;kpd; mspj;J xU ; ; ; ; ; ; ;; ; ; ; ; ; ;; ; ; ; ; ; ;
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gq;F ngWgthpd; ngah; ; ; ;; ; ;; ; ;  :  
gq;F ngWgthpd; ; ;; ;; ; taJ : 
  gq;F ngWgth; ,jid ; ;; ;; ;
Fwpf;fTk;; ;; ;; ; 
1. ehd; NkNy Fwpg;gpl;Ls;s kUj;J Ma;tpd; 
tptuq;fis ehd; gbj;J Ghpe;J nfhz;Nld;. 
vd;Dila re;Njfq;fis Nfl;fTk;> mjw;fhd jFe;j 
tpsf;fq;fis ngwTk; tha;g;gspf;fg;gl;Ls;sJ vd 
mwpe;J nfhz;Nld;. 
 
2. ehd; ,t;tha;tpy; jd;dpr;irahf jhd; gq;Nfw;fpNwd;. 
ve;j fhuzj;jpdhNyh ve;j fl;lj;jpYk;> ve;j rl;l 
rpf;fYk; cl;glhky; ehd; ,t;tha;tpy; ,Ue;J tpyfp 
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ghh;g;gjw;F nfhs;fpNwd;. ehd; Ma;tpy; ,Ue;J 
tpyfpf; nfhz;lhYk; ,J nghUe;Jk; vd mwpfpNwd;. 
 
4. ,e;j Ma;tpd; %yk; fpilf;Fk; jftiyNah> 
KbitNah gad;gLj;jpf; nfhs;s kWf;f khl;Nld;. 
 
5. ,e;j Ma;tpy; gq;F nfhs;s xg;Gf; nfhs;fpNwd;. 
vdf;F nfhLf;fg;gl;l mwpTiufspd; gb ele;J 
nfhs;tJld; Ma;it Nkw;nfhs;Sk; kUe;J mzpf;F 
cz;ikAld; ,Ug;Ngd; vd cWjpaspf;fpNwd;. vd; 
cly; eyk; ghjpf;fg;gl;lhNyh> my;yJ vjph;ghuhf 
tof;fj;jpw;F khwhd Neha;Fwp njd;gl;lhNyh clNd 
,ij kUj;Jt mzpaplk; njhptpg;Ngd; vd cWjp 
mspf;fpNwd;. 
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ngah; kw;Wk; tpyhrk; ___________________________________________________________ 
INFORMED CONSENT FORM 
Study Title : A Randomized, Open Labelled, Single Centered Study Of 
Metformin In Preventing Metabolic  Syndrome Associated With Initiation Of 
Atypical Antipsychotic Therapy In Adolescents And Young  Adults 
StudyNumber__________________________________________________ 
Subject's Full Name _____________________________________ 
Date of Birth/Age_____________________________ 
Address 
_____________________________________________________________
_____________________________________________________________ 
 
1. I confirm that I have read and understood the information sheet dated 
for the above study and have had the opportunity to ask questions. or I 
have been explained the nature of the study by the Investigator and 
had the opportunity to ask questions 
2. I understand that my participation in the study is voluntary and that I 
am free to withdraw at anytime, without giving any reason and 
without my medical care or legal rights being affected. 
3. I understand that the sponsor of the clinical trial/project, others 
working on the Sponsor's behalf,the Ethics Committee and the 
regulatory authorities will not need my permission to look at my 
health records both in respect of the current study and any further 
research that may be conducted in relation to it, even if I withdraw 
from the trial. However, I understand that my Identity will not be 
revealed in any information released to third parties or published. 
4. I agree not to restrict the use of any data or results that arise from this 
study provided such a use isonly for scientific purpose(s) 
5. I agree to take part in the above study 
 
Signature (or Thumb impression) of the Subject/Legally Acceptable 
Representative: ____________________ 
Signatory's Name ______________________________________  
Date __________________________ 
Signature of the Investigator _____________________________ 
Date __________________________ 
Study Investigator's Name ________________________________ 
Signature of the Witness ________________________________ Date 
__________________________ 
Name of the Witness 
  
APPENDIX (iii) 
STUDY  PROFORMA 
NAME      :                                        AGE/SEX : 
ADDRESS      : 
CONTACT NUMBER    :  
H/O       :  
TAKING TREATMENT SINCE  : 
GENERAL EXAMINATION  : 
BP                       :                                 PULSE RATE : 
CVS                    : 
RS                       : 
ABDOMEN        : 
CNS                    : 
INVESTIGATIONS DURING SCREENING : 
a) Anthropometric measurements : 
 Height  
 Weight 
 Waist circumference 
b) Blood investigations : 
 Complete  blood  count  
 Fasting  blood  sugar  
 Serum  urea  
 Serum  creatinine   
 Liver  function  tests   
 Routine  urine  analysis  
 Fasting  lipid  profile . 
PARAMETERS ASSESSED : 
 BASELINE END OF 3 
MONTHS 
END OF 6 
MONTHS 
WEIGHT    
HEIGHT    
BODY MASS INDEX    
WAIST 
CICUMFERENCE 
   
FASTING BLOOD 
GLUCOSE 
   
FASTING 
TRIGLYCERIDES 
   
 
 
BASELINE 3 MTHS 6 MTHS BASELINE 3 MTHS 6 MTHS BASELINE 3 MTHS 6 MTHS BASELINE 3 MTHS 6 MTHS
1 1 26 1 22.1 22.3 23.6 82 82 84 90 92 100 132 141 156
1 2 34 2 21.8 22.9 24.08 80 89 90 68 87 86 185 139 360
1 3 19 1 21.5 22.9 24.4 129 130 132 143 149 156 77 90 110
1 4 40 1 22.9 25.7 27 94 95 98 100 108 115 251 261 245
1 5 25 1 22.2 22.5 23.2 95 97 100 81 101 98 116 136 129
1 6 23 1 22.5 22.9 23.6 85 85 86 83 131 142 90 120 126
1 7 34 1 23.9 24.2 24.9 82 83 84 86 111 126 157 168 179
1 8 40 2 19.5 20.8 22.5 75 75 76 86 98 110 123 136 148
1 9 33 2 27.7 28.1 29 98 99 99 76 110 138 119 156 178
1 10 21 2 21.8 22.7 23.6 98 99 101 83 126 141 42 78 96
1 11 30 2 24.6 25.4 26.3 78 79 80 60 121 117 76 118 127
1 12 37 2 21.6 21.6 22.4 73 77 80 92 100 108 156 225 240
1 13 28 2 23.6 24.5 25.3 84 87 89 84 98 121 71 101 152
1 14 30 2 22.6 23 23.7 84 86 86 101 103 98 282 285 296
1 15 28 1 22.3 23.4 24.5 75 78 80 96 110 121 88 96 128
1 16 39 2 17.3 18.6 20.2 79 82 90 88 95 112 123 146 151
1 17 35 1 26.2 26.6 27.6 93 102 98 79 139 149 111 266 260
1 18 33 2 34.2 35.2 36.2 95 98 101 99 101 108 86 92 112
1 19 33 1 18.1 18.5 18.1 72 84 79 109 126 148 197 290 121
1 20 24 2 23.7 25.9 25 75 78 80 142 113 105 100 239 100
1 21 30 2 16.9 17.8 20 67 69 71 96 112 126 107 125 138
1 22 40 2 29.3 29.7 30.5 93 96 97 95 98 100 94 126 134
1 23 33 1 26.7 27 27.4 101 105 104 102 116 122 137 151 146
1 24 35 2 23.5 24.4 25.3 81 83 83 102 112 110 225 236 251
1 25 39 1 17.5 18.3 19.4 87 88 90 134 146 140 156 181 178
1 26 29 2 19 19.9 20.8 65 67 68 79 96 110 123 161 158
1 27 32 2 31.2 32 32.9 97 98 99 69 71 86 142 156 176
1 28 30 1 29.4 29.8 30.5 98 98 100 187 182 175 197 212 201
1 29 34 1 25.4 25.4 26.6 86 95 94 108 121 135 88 105 123
1 30 32 1 19.5 21.5 23.4 72 78 80 66 78 80 79 86 116
1 31 20 1 24.3 25.2 26.4 78 83 82 87 96 101 248 251 245
1 32 24 1 22.5 22.9 23.7 79 80 80 62 78 88 58 66 97
1 33 36 2 29.5 32 32.9 105 108 112 85 108 124 180 470 387
1 34 31 2 25.6 24.3 25.6 94 95 95 89 150 142 182 220 227
1 35 20 1 21.5 22.1 22.8 87 88 89 61 64 75 72 95 87
1 36 31 2 27.5 28.8 29.7 104 102 105 74 82 95 377 390 416
1 37 20 2 17.8 19.6 21.3 65 69 70 68 77 110 224 337 326
1 38 26 1 19.5 20.3 21.1 72 74 75 106 67 126 155 160 180
1 39 32 1 17.6 18.8 20 72 73 73 97 119 132 132 149 168
1 40 31 1 24.7 27.9 28.8 92 92 94 65 87 118 137 322 357
1 41 23 1 20 20.7 21.4 77 78 80 94 126 145 220 255 273
1 42 28 1 21.8 22.5 23.2 80 82 84 98 113 136 156 172 194
1 43 27 1 18.4 19 19.7 78 79 81 90 113 126 150 168 187
1 44 26 1 21.2 24 24.8 81 84 86 68 73 108 143 166 182
1 45 28 1 20.4 23.7 24.7 86 88 89 70 96 108 178 186 201
1 46 25 2 18.7 19.1 19.8 78 80 81 87 98 118 151 188 196
1 47 30 2 15.6 16.9 18.2 74 76 77 81 95 121 81 138 179
1 48 21 1 20.2 21.3 22 80 82 83 76 108 132 254 241 261
S.NOGROUP
GROUP I (RISPERIDONE ALONE)
    BODY MASS INDEX   WAIST CIRCUM (IN CMS)            FASTING BS ING BS (IN GM/DL)              TGL (IN MG%)SEX M-
1,F-2
AGE
BASELINE 3 MTHS 6 MTHS BASELINE 3 MTHS 6 MTHS
BASELIN
E 3 MTHS 6 MTHS
BASELI
NE 3 MTHS 6 MTHS
2 1 32 1 22.8 22.4 22.1 85 85 84 101 118 96 161 150 136
2 2 25 1 25.3 24.4 23.1 87 0 86 118 116 86 88 100 98
2 3 30 2 27.9 26.3 24.2 92 91 90 128 119 96 104 98 95
2 4 27 1 22.6 23.7 21.8 86 86 85 73 93 86 96 168 127
2 5 33 2 34 34 33.6 120 120 118 81 155 92 70 168 104
2 6 26 1 22.3 21.9 21.5 68 68 67 71 86 91 125 132 112
2 7 31 1 27.3 26.6 25.8 92 92 90 80 85 76 185 172 161
2 8 33 1 23.6 23.6 22.9 72 72 71 109 112 96 197 195 174
2 9 20 1 24.6 24.1 23.3 73 73 72 61 72 65 157 161 145
2 10 35 1 24.4 23.6 22.9 88 88 87 116 118 110 144 152 142
2 11 31 2 22.7 22.2 21.8 91 90 90 127 123 112 156 158 143
2 12 18 1 24.2 22.8 22.1 89 86 83 83 74 75 94 87 85
2 13 35 1 23.8 22.9 22.5 73 73 72 52 78 60 105 112 106
2 14 29 2 32.9 31.6 30.3 105 103 102 151 145 143 425 386 372
2 15 22 1 27.4 26.2 25.1 74 74 73 67 75 72 90 98 93
2 16 26 1 25.8 24.8 24.4 90 90 89 60 72 68 243 236 220
2 17 31 1 25.4 24.6 23.8 67 67 66 123 121 109 157 152 145
2 18 24 1 22.1 21.1 20.8 80 80 78 60 72 65 130 127 112
2 19 38 2 31.9 30.4 28.5 109 107 105 128 118 96 178 156 158
2 20 32 1 25 24.6 23.9 81 80 78 152 145 136 148 132 128
2 21 29 2 25.3 24.5 23.6 105 105 104 124 114 96 110 126 107
2 22 25 1 25.9 25.1 24.4 97 96 96 196 175 168 184 177 172
2 23 24 1 25.1 24.8 24.4 88 87 86 163 155 148 156 145 142
2 24 30 1 24.2 23.8 22.3 80 79 78 118 92 89 188 139 142
2 25 30 2 28.2 27.1 26.3 101 100 99 79 85 99 172 165 158
2 26 32 1 24.2 23.8 23.8 92 91 91 93 100 95 132 142 128
2 27 32 2 42.8 42.3 39.2 119 119 118 109 89 98 110 130 126
2 28 29 1 24.3 23.9 23.1 86 87 86 78 84 82 148 136 142
2 29 23 2 30.9 30 28.5 96 95 95 112 101 100 73 86 91
2 30 34 1 25.1 24.2 23.4 91 90 90 74 89 92 515 458 465
2 31 23 1 24.4 24 23.7 74 73 71 66 78 85 88 82 90
2 32 25 2 25 24.6 24.6 79 78 77 121 112 110 127 132 112
2 33 30 2 22.8 22.4 22.4 94 93 90 82 95 101 134 142 126
2 34 28 2 23.9 23.5 23.1 88 87 85 76 85 80 277 243 212
2 35 23 2 21.2 20.8 20.8 83 82 80 137 121 118 111 126 116
2 36 25 1 22.3 21.9 21.6 81 80 78 75 83 68 87 109 94
2 37 26 2 41.6 39.5 37.5 113 112 110 101 96 98 203 198 176
2 38 28 1 24.6 24.1 23.3 72 71 70 81 97 78 179 168 165
2 39 22 1 22.8 21.8 21.3 88 87 85 79 87 76 114 126 118
2 40 27 2 21.5 21 20.5 85 85 84 84 96 78 276 255 221
2 41 30 2 28.6 27.7 26.3 100 98 97 93 81 85 176 143 158
2 42 34 1 32.7 31.6 30.9 111 109 109 107 98 95 246 230 210
2 43 35 2 28.8 27.9 26.7 107 107 105 79 78 65 187 162 145
2 44 33 2 27 26.2 25.4 108 107 105 127 113 96 186 165 151
2 45 30 2 30.5 29.6 28.7 100 98 97 112 108 101 194 182 170
2 46 29 1 23.5 23.1 22.8 85 85 83 71 85 82 166 153 155
2 47 28 1 25.7 24.9 24.5 74 74 72 116 110 107 167 155 142
2 48 38 2 23.1 22.1 21.1 86 86 85 83 94 89 118 138 126
S.NOGROUP
GROUP II (RISPERIDONE + METFORMIN)
          WAIST CIRCUM (IN CMS)          FASTING BS (IN MG%)              TGL (IN MG%)BODY MASS INDEX
SEX M-1 , F-
2AGE
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